Podcasts about zhang y

Get your sprouter here: https://shop.drfuhrman.com/sprouter/References:Fouad AA, Rehab FM. Effect of germination time on proximate analysis, bioactive compounds and antioxidant activity of lentil (Lens culinaris Medik.) sprouts. Acta Sci Pol Technol Aliment 2015, 14:233-246.Guo X, Li T, Tang K, Liu RH. Effect of germination on phytochemical profiles and antioxidant activity of mung bean sprouts (Vigna radiata). J Agric Food Chem 2012, 60:11050-11055.Ebert AW, Chang C-H, Yan M-R, Yang R-Y. Nutritional composition of mungbean and soybean sprouts compared to their adult growth stage. Food Chemistry 2017, 237:15-22.Mubarak AE. Nutritional composition and antinutritional factors of mung bean seeds (Phaseolus aureus) as affected by some home traditional processes. Food Chemistry 2005, 89:489-495.Erba D, Angelino D, Marti A, et al. Effect of sprouting on nutritional quality of pulses. International Journal of Food Sciences and Nutrition 2019, 70:30-40.Fahey JW, Zhang Y, Talalay P. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc Natl Acad Sci U S A 1997, 94:10367-10372.

Send us a textSupplemental Iron and Recombinant Erythropoietin for Anemia in Infants Born Very Preterm: A Survey of Clinical Practice in Europe.Reibel-Georgi NJ, Scrivens A, Heeger LE, Lopriore E, New HV, Deschmann E, Stanworth SJ, Carrascosa MA, Brække K, Cardona F, Cools F, Farrugia R, Ghirardello S, Krivec JL, Matasova K, Muehlbacher T, Sankilampi U, Soares H, Szabó M, Szczapa T, Zaharie G, Roehr CC, Fustolo-Gunnink S, Dame C; Neonatal Transfusion Network.J Pediatr. 2025 Jan;276:114302. doi: 10.1016/j.jpeds.2024.114302. Epub 2024 Sep 13.PMID: 39277077 Free article. Enteral nutritional practices in extremely preterm infants: a survey of U.S. NICUs.Romero-Lopez M, Naik M, Holzapfel LF, Tyson JE, Pedroza C, Ahmad KA, Rysavy MA, Carlo WA, Zhang Y, Tibe C, Salas AA.J Perinatol. 2024 Dec 9. doi: 10.1038/s41372-024-02198-6. Online ahead of print.PMID: 39653781 No abstract available.As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textEnteral nutritional practices in extremely preterm infants: a survey of U.S. NICUs.Romero-Lopez M, Naik M, Holzapfel LF, Tyson JE, Pedroza C, Ahmad KA, Rysavy MA, Carlo WA, Zhang Y, Tibe C, Salas AA.J Perinatol. 2024 Dec 9. doi: 10.1038/s41372-024-02198-6. Online ahead of print.PMID: 39653781 No abstract available.As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Pour accéder à l'intégralité de ce podcast et écouter chaque semaine un nouvel épisode du Quart d'Heure Véto, c'est très simple, il vous suffit de vous abonner en cliquant sur ce lien : https://m.audiomeans.fr/s/S-yUNSBZSR Notes et référencesArticle : Zhang X, Mai Z, Gao Y, Zhao X, Zhang Y. Selecting potential biomarkers of plasma proteins in mares with endometritis. Equine Vet J. 2024 Jul;56(4):660-669. doi: 10.1111/evj.14092. Epub 2024 Apr 14. PMID: 38616335.Retrouvez toute la synthèse sur la fiche podcast juste ici : https://audmns.com/xCvrZluPour nous suivre :1. Abonnez-vous à notre chaine pour profiter de l'intégralité des épisodes : Le Quart d'Heure Véto : décrypte et résume en moins de 15 min un article de biblio véto - Sur abonnement uniquementLe Véto du Mois : Partagez le temps d'une interview l'expérience de vétérinaires emblématiques de notre milieu, des rencontres conviviales, comme si nous étions dans votre salon au coin du feu. Podcasts bonus au fil des inspirations... 2. Le ScopeNous partageons avec vous nos dernières découvertes, inspirations, pistes de réflexion, nouveautés… À découvrir et utiliser dès maintenant, TOUT DE SUITE, dans votre quotidien de vétérinaire, de manager, de vie personnelle, de chef d'entreprise… Et tout cela en moins de 5 minutes top chrono un à 2 mardis par mois ! Je souhaite recevoir mon Scope : https://vetmasterclass.com/lescope/ 3. Contactez-nous, suivez-nous et donnez nous votre avis ! Des sujets que vous souhaiteriez approfondir, des références à partager, ou nous faire part de vos feed-backs :Abonnez-vous à notre chaine, donnez nous des étoiles, un commentaire et partagez autour de vous !Sur notre site : https://vetmasterclass.com/Sur Facebook : https://www.facebook.com/VmHorseSur Instagram : https://www.instagram.com/vetmasterclass/Sur YouTube : https://www.youtube.com/channel/UC18ovcWk9e-mFiTL34OQ03gSur Linkedin : https://www.linkedin.com/company/vetmasterclass-horse/about/Belle journée à tous, Et continuez à vivre votre métier avec Passion !

Neste episódio do Journal Club, as apresentadoras Mariana e Marôla mergulham em vários estudos impactantes em neonatologia. Elas apresentam uma série de artigos sobre o tratamento do canal arterial patente (PCA), discutindo tratamentos farmacológicos, técnicas de fechamento transcateter e novas diretrizes de prática clínica. A conversa destaca o cenário em evolução do tratamento do PCA e a necessidade de pesquisas mais robustas, para que esse assunto deixe de ser a eterna polêmica da semana em neonatologia.Ao longo do episódio, Mariana e Marôla fornecem comentários perspicazes sobre as implicações clínicas desses estudos, tornando pesquisas complexas acessíveis aos ouvintes e, ao mesmo tempo, enfatizando a necessidade de investigação contínua em áreas-chave do atendimento neonatal. Os artigos abordados no episódio de hoje do podcast podem ser encontrados aqui:1. Acetaminophen for Patent Ductus Arteriosus and Risk of Mortality and Pulmonary MorbidityJensen EA, DeMauro SB, Rysavy MA, Patel RM, Laughon MM, Eichenwald EC, Do BT, Das A, Wright CJ; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network.Pediatrics. 2024 Jul 16:e2023065056. https://pubmed.ncbi.nlm.nih.gov/39011550/#:~:text=Acetaminophen%20was%20associated%20with%20increased,%25%20CI%200.91%2D1.82).2. Transcatheter and Surgical Ductus Arteriosus Closure in Very Low Birth Weight Infants: 2018-2022.Leahy BF, Edwards EM, Ehret DEY, Soll RF, Yeager SB, Flyer JN.Pediatrics. 2024 Jul 15:e2024065905. https://pubmed.ncbi.nlm.nih.gov/39005106/#:~:text=Transcatheter%20closure%20increased%20from%2029.8,0.94%3B%200.89%2D1.01).3. Long term follow-up of patients with patent ductus arteriosus after transcatheter closure.Peng Y, Cheng Z, Zhang Y, Yi Q.Pediatr Res. 2024 Jun 14. doi: 10.1038/s41390-024-03317-x. Online ahead of print.PMID: 38877281 https://pubmed.ncbi.nlm.nih.gov/38877281/4. Procedural closure of the patent ductus arteriosus in preterm infants: a clinical practice guideline.Mitra, S., Bischoff, A.R., Sathanandam, S. et al. Procedural closure of the patent ductus arteriosus in preterm infants: a clinical practice guideline. J Perinatol (2024). https://doi.org/10.1038/s41372-024-02052-9https://www.nature.com/articles/s41372-024-02052-9#:~:text=Overall%2C%20the%20panel%20felt%20that,persistent%20large%20transductal%20shunt%20on Não esqueça: você pode ter acesso aos artigos do nosso Journal Club no nosso site: https://www.the-incubator.org/podcast-1 Se estiver gostando do nosso Podcast, por favor deixe sua avaliação no seu aplicativo favorito e compartilhe com seus colegas. O nosso objetivo é democratizar a informação. Se quiser entrar em contato, nos mandar sugestões, comentários, críticas e elogios, manda um e-mail pra gente: incubadora@the-incubator.org

Send us a Text Message.Long term follow-up of patients with patent ductus arteriosus after transcatheter closure.Peng Y, Cheng Z, Zhang Y, Yi Q.Pediatr Res. 2024 Jun 14. doi: 10.1038/s41390-024-03317-x. Online ahead of print.PMID: 38877281As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Dr. Natalie Scheeler, a naturopathic doctor specializing in integrative treatments for gastrointestinal conditions, shares her perspective and valuable insights on gut health. She discusses the difference between naturopathic doctors and traditional MDs, the use of fecal microbiota transplant (FMT) and Helminthic therapies in treating inflammatory bowel disease (IBD), the impact of food and probiotics on IBD, and trends in flare management and remission. Dr. Scheeler also provides information about her practice, Modrn Med, and offers a final message of hope and encouragement for patients seeking alternative or complementary treatment options. Takeaways Naturopathic doctors focus on preventative medicine and finding the root cause through a whole person approach using integrative treatments that can be used alongside conventional therapies. Fecal microbiota transplant (FMT) and Helminthic therapies are alternative treatments for IBD that show promise in inducing remission and maintaining gut health. Diet plays a significant role in creating a diverse microbiome. Modrn Med is an integrative and functional medicine practice that offers telehealth consultations and works in collaboration with other healthcare providers. There are other treatment options available for patients who have not found success with conventional therapies, and it is important to work with a knowledgeable practitioner to explore these options. Topics covered in the interview Difference Between Naturopathic Doctors (ND) and traditional doctors (MD or DO) Integrative Treatments for Gastrointestinal Conditions Fecal Microbiota Transplant (FMT) Impact of Food and Probiotics on IBD Trends in Flare Management and Remission Helminthic Therapies About Modrn Med From the show Stephanie: What are some of the trends that you've seen with helping people to get out of a flare and into remission? Dr. Scheeler: …the dietary aspect is a large trend I'm seeing I think, too, with social media. There's just the ability to spread so much information and so that is oftentimes how people coming into our office and have said, ‘I've tried these diets' or ‘I've done these diets' versus us kind of introducing them to that idea. So that's interesting. The other one is an herb called Qing Dai. It's a Chinese herb…which is an herb that can be really helpful for inducing remission, typically. We usually reserve it for remission induction versus maintenance therapy because there are some safety risks to that…I would always, always recommend working with a provider who's familiar with that herb…something that is important to say is that natural medicine isn't always safer, and it isn't always safe in general. There is risks associated with any treatments that you do. And so knowing those risks, having somebody who is familiar with those risks is important, especially if you are on the kind of quote-unquote conventional medications and add this stuff in, there could be interactions. Stephanie: Can you talk a little bit about the Modrn Med practice and what types of patients you see? Dr. Scheeler: Yeah, so ModernMed, we are a practice, we are all naturopathic doctors. There's four of us there. And we do integrative and functional medicine. A large part of our practice is gastrointestinal disease, including inflammatory bowel disease. I personally see patients exclusively via telehealth…but there is a location in LA, too, if people are interested. With that, since I do telehealth, I'm licensed in California, Arizona, Maryland, Vermont, and Connecticut, as of now. But all of us depending can either see you as patient if we're licensed in that state or do what we consider educational consults. So with patients who live out of state, we can share some of this information with you and help you do things safely or talk with your provider too…it's very common for us to work with other providers, especially myself working with gastroenterologists. I think when we all work as a team is when we get the best outcomes. And so patients, who may be in a state that we're not licensed in, we're comfortable talking to providers and usually there's no issues with that as long as we explain what we're doing. We always do evidence-based medicine. So as long as we share, even if they're not familiar with it off the bat, most people are open to working together and helping the patient out. Links and studies from the show Modern Med: https://www.modrnmed.com/dr-natalie-scheeler FMT for UC: Nishida A, Inoue R, Inatomi O, Bamba S, Naito Y, Andoh A. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018;11(1):1-10. doi:10.1007/s12328-017-0813-5 (PMID: 29285689)  FMT for CD: Zhou S, Cui Y, Zhang Y, Zhao T, Cong J. Fecal microbiota transplantation for induction of remission in Crohn's disease: a systematic review and meta-analysis. Int J Colorectal Dis. 2023;38(1):62. Published 2023 Mar 8. doi:10.1007/s00384-023-04354-4 (PMID: 36882658)  Helminthic Therapy in CD (Trichuris suis specific): Schölmerich J, Fellermann K, Seibold FW, et al. A Randomised, Double-blind, Placebo-controlled Trial of Trichuris suis ova in Active Crohn's Disease. J Crohns Colitis. 2017;11(4):390-399. doi:10.1093/ecco-jcc/jjw184 (PMID: 27707789)  Helminthic Therapy in CD (Trichuris suis specific):  Garg SK, Croft AM, Bager P. Helminth therapy (worms) for induction of remission in inflammatory bowel disease. Cochrane Database Syst Rev. 2014;2014(1):CD009400. Published 2014 Jan 20. doi:10.1002/14651858.CD009400.pub2 (PMID: 24442917)  Paper co-written by Dr. Scheeler on Qing Dai (Pronounced "Ching Dye") a.k.a. Indigo Naturalis: https://www.naturalmedicinejournal.com/journal/clinical-application-of-indigo-naturalis Support the podcast ❤️ at https://www.crohnsfitnessfood.com Get your copy of Crohn's Fitness Food and My Rocky Road to Health, Shop my favorite products, Read my favorite books, Subscribe to the podcast, Send a little love/coffee

In this episode of BackTable OBGYN, renowned reproductive endocrinologist and minimally invasive gynecologic surgeon Dr. Charles (Chuck) Miller delves into the topic of isthmoceles, a common yet often overlooked complication of C-sections, and shares his best practices for repair. Dr. Miller shares his extensive experience in diagnosing and treating isthmoceles, discussing various surgical techniques including hysteroscopic, laparoscopic, and robotic-assisted resection. He emphasizes the importance of an aggressive surgical approach for achieving higher success rates in terms of future fertility and resolving symptoms such as abnormal bleeding. Moreover, Dr. Miller highlights the need for standardized treatment protocols and reflects on the mentorship, the ongoing journey of learning and adapting in medicine, and the noble profession of healthcare. The episode offers insightful perspectives on a lesser-known gynecologic issue, underscores the value of experience and mentorship in medicine, and advocates for concerted efforts toward establishing best practices in surgical procedures. --- SHOW NOTES 00:00 - Introduction 07:18 - Defining Isthmocele and the History of Isthmocele 10:00 - The Diagnosis of Isthmocele and Its Impact on Fertility 19:31 - Exploring Surgical Techniques for Isthmocele Repair 27:54 - Understanding Hysteroscopic Resection 30:12 - Addressing C-Section Ectopics and Isthmocele Repairs 36:46 - Adapting the Surgical Approach to Different Patient Scenarios 39:35 - Postoperative Complications and Safety Measures 40:55 - The Future of Isthmocele: Surgical Standardization 50:51 - Closing Thoughts and Acknowledgements --- RESOURCES Ban Y, Shen J, Wang X, Zhang T, Lu X, Qu W, Hao Y, Mao Z, Li S, Tao G, Wang F, Zhao Y, Zhang X, Zhang Y, Zhang G, Cui B. Cesarean Scar Ectopic Pregnancy Clinical Classification System With Recommended Surgical Strategy. Obstet Gynecol. 2023 May 1;141(5):927-936. doi: 10.1097/AOG.0000000000005113. Epub 2023 Apr 5. PMID: 37023450; PMCID: PMC10108840.

Jamie Hartmann-Boyce and Nicola Lindson discuss emerging evidence in e-cigarette research interview Reto Auer, Bern University, Switzerland. Associate Professor Jamie Hartmann-Boyce and Dr Nicola Lindson discuss the new evidence in e-cigarette research and interview Professor Reto Auer, primary care physician and clinical researcher from the Institute of Primary Health Care (BIHAM), University of Bern. Reto Auer is Head of the Substance Use Unit, where he leads a variety of research projects, including a large randomized controlled trial designed to test the efficacy, safety and toxicology of nicotine e-cigarettes. Jamie Hartmann-Boyce interviews Reto Auer about his new study published in the New England Journal of Medicine ‘Electronic nicotine delivery systems for smoking cessation'. This trial randomized 1246 participants: 622 to free e-cigarettes and e-liquids, standard-of-care smoking-cessation counselling, and optional (not free) nicotine-replacement therapy; and 624 participants to a control group, which received standard counselling and a voucher, which they could use for any purpose, including nicotine-replacement therapy. This study was funded by the Swiss National Science Foundation and others and registered as ESTxENDS NCT03589989. The percentage of participants with validated continuous abstinence from tobacco smoking was 28.9% in the intervention group and 16.3% in the control group (relative risk, 1.77; 95% confidence interval, 1.43 to 2.20). The study concluded that adding e-cigarettes to standard smoking-cessation counselling resulted in greater abstinence from tobacco use among smokers than smoking-cessation counselling alone. DOI: 10.1056/NEJMoa2308815 This podcast is a companion to the electronic cigarettes Cochrane living systematic review and shares the evidence from the monthly searches. Our literature searches carried out on 1st February found the following 1 new study by Lin 2024 (Lin, H-X, Liu Z, Hajek P, Zhang W-T, Wu Y, Zhu B-C, Liu H-H, Xiang Q, Zhang Y, Li S-B, Pesola F, Wang Y-Y, Efficacy of Electronic Cigarettes vs Varenicline and Nicotine Chewing Gum as an Aid to Stop Smoking: A Randomized Clinical Trial, JAMA internal medicine / 2024;(101589534).) 3 new ongoing studies: NCT06169813, E-cigarette Harm Reduction Among PLWHA in South Africa. ISRCTN14068059, E-cigarettes for smoking cessation and reduction in people with a mental illness. Hameed A, Malik D, Clinical study protocol on electronic cigarettes and nicotine pouches for smoking cessation in Pakistan: a randomized controlled trial, Trials / 2024;25(1):9 3 papers linked to studies included in the review: Scheibein F, McGirr K, Morrison A, Roche W, Wells JSG, Correction to: an exploratory non-randomized study of a 3-month electronic nicotine delivery system (ENDS) intervention with people accessing a homeless supported temporary accommodation service (STA) in Ireland, Harm reduction journal 2021;18(1):113 Pesola F, Smith KM, Phillips-Waller A, Przulj D, Griffiths C, Walton R, McRobbie H, Coleman T, Lewis S, Whitemore R, Clark M, Ussher M, Sinclair L, Seager E, Cooper S, Bauld L, Naughton F, Sasieni P, Manyonda I, Hajek P, Safety of e-cigarettes and nicotine patches as stop-smoking aids in pregnancy: Secondary analysis of the Pregnancy Trial of E-cigarettes and Patches (PREP) randomized controlled trial, Addiction (Abingdon, England) / 2024 Trigg J, Rich J, Williams E, Gartner CE, Guillaumier A, Bonevski B, Perspectives on limiting tobacco access and supporting access to nicotine vaping products among clients of residential drug and alcohol treatment services in Australia, Tobacco control 2023 For further details see our webpage under 'Monthly search findings': https://www.cebm.ox.ac.uk/research/electronic-cigarettes-for-smoking-cessation-cochrane-living-systematic-review-1 Associate Professor Jamie Hartmann-Boyce and Dr Nicola Lindson discuss the new evidence in e-cigarette research and interview Professor Reto Auer, primary care physician and clinical researcher from the Institute of Primary Health Care (BIHAM), University of Bern. Reto Auer is Head of the Substance Use Unit, where he leads a variety of research projects, including a large randomized controlled trial designed to test the efficacy, safety and toxicology of nicotine e-cigarettes. Jamie Hartmann-Boyce interviews Reto Auer about his new study published in the New England Journal of Medicine ‘Electronic nicotine delivery systems for smoking cessation'. This trial randomized 1246 participants: 622 to free e-cigarettes and e-liquids, standard-of-care smoking-cessation counselling, and optional (not free) nicotine-replacement therapy; and 624 participants to a control group, which received standard counselling and a voucher, which they could use for any purpose, including nicotine-replacement therapy. This study was funded by the Swiss National Science Foundation and others and registered as ESTxENDS NCT03589989. The percentage of participants with validated continuous abstinence from tobacco smoking was 28.9% in the intervention group and 16.3% in the control group (relative risk, 1.77; 95% confidence interval, 1.43 to 2.20). The study concluded that adding e-cigarettes to standard smoking-cessation counselling resulted in greater abstinence from tobacco use among smokers than smoking-cessation counselling alone. DOI: 10.1056/NEJMoa2308815 This podcast is a companion to the electronic cigarettes Cochrane living systematic review and shares the evidence from the monthly searches. Our literature searches carried out on 1st February found the following 1 new study by Lin 2024 (Lin, H-X, Liu Z, Hajek P, Zhang W-T, Wu Y, Zhu B-C, Liu H-H, Xiang Q, Zhang Y, Li S-B, Pesola F, Wang Y-Y, Efficacy of Electronic Cigarettes vs Varenicline and Nicotine Chewing Gum as an Aid to Stop Smoking: A Randomized Clinical Trial, JAMA internal medicine / 2024;(101589534).) 3 new ongoing studies: NCT06169813, E-cigarette Harm Reduction Among PLWHA in South Africa. ISRCTN14068059, E-cigarettes for smoking cessation and reduction in people with a mental illness. Hameed A, Malik D, Clinical study protocol on electronic cigarettes and nicotine pouches for smoking cessation in Pakistan: a randomized controlled trial, Trials / 2024;25(1):9 3 papers linked to studies included in the review: Scheibein F, McGirr K, Morrison A, Roche W, Wells JSG, Correction to: an exploratory non-randomized study of a 3-month electronic nicotine delivery system (ENDS) intervention with people accessing a homeless supported temporary accommodation service (STA) in Ireland, Harm reduction journal 2021;18(1):113 Pesola F, Smith KM, Phillips-Waller A, Przulj D, Griffiths C, Walton R, McRobbie H, Coleman T, Lewis S, Whitemore R, Clark M, Ussher M, Sinclair L, Seager E, Cooper S, Bauld L, Naughton F, Sasieni P, Manyonda I, Hajek P, Safety of e-cigarettes and nicotine patches as stop-smoking aids in pregnancy: Secondary analysis of the Pregnancy Trial of E-cigarettes and Patches (PREP) randomized controlled trial, Addiction (Abingdon, England) / 2024 Trigg J, Rich J, Williams E, Gartner CE, Guillaumier A, Bonevski B, Perspectives on limiting tobacco access and supporting access to nicotine vaping products among clients of residential drug and alcohol treatment services in Australia, Tobacco control 2023 For further details see our webpage under 'Monthly search findings': https://www.cebm.ox.ac.uk/research/electronic-cigarettes-for-smoking-cessation-cochrane-living-systematic-review-1 For more information on the full Cochrane review updated in January 2024 see: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010216.pub8/full This podcast is supported by Cancer Research UK. This podcast is supported by Cancer Research UK.

Insulin icodec is the first class of long-acting insulin to be administered only once a week. Join host, Jen Moulton, as she discusses the safety and efficacy of insulin icodec with guest, Geoff Wall.The GameChangerInsulin icodec is the first of the ultra long-acting insulins with once weekly dosing. Multiple clinical studies have suggested these pharmacokinetics work. A new meta-analysis suggests that insulin icodec is more effective than other basal insulins and at least as safe concerning hypoglycemia.Jen Moulton, RPhPresident + FounderCEimpactGeoff Wall, PharmD, BCPS, FCCP, BCGPProfessor of Pharmacy Practice, Drake UniversityInternal Medicine/Critical Care, UnityPoint Health ReferenceWang P, Zhang Y, Xu W, et al. Efficacy and Safety of Once-Weekly Insulin Regimes on Glycemic Control for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Diabetol Metab Syndr. 2024 Jan 3;16(1):3. doi: 10.1186/s13098-023-01240-5. PMID: 38172995; PMCID: PMC10763463.https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-023-01240-5#Sec19 Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE Information Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Explain the chemical and structural changes that make icodec different from other basal insulins 2. Discuss the results of the meta-analysis about insulin icodec0.05 CEU/0.5 HrUAN: 0107-0000-24-043-H01-PInitial release date: 1/29/2024Expiration date: 1/29/2025Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Welcome to the Social-Engineer Podcast: The Doctor Is In Series – where we will discuss understandings and developments in the field of psychology.   In today's episode, Chris and Abbie are discussing music and the senses; how it can influence our mood, “seeing” sounds, and the various ways music can shape our health. [Dec 4, 2023]   00:00 - Intro 00:17 - Dr. Abbie Maroño Intro 01:15 - Intro Links -          Social-Engineer.com - http://www.social-engineer.com/ -          Managed Voice Phishing - https://www.social-engineer.com/services/vishing-service/ -          Managed Email Phishing - https://www.social-engineer.com/services/se-phishing-service/ -          Adversarial Simulations - https://www.social-engineer.com/services/social-engineering-penetration-test/ -          Social-Engineer channel on SLACK - https://social-engineering-hq.slack.com/ssb -          CLUTCH - http://www.pro-rock.com/ -          innocentlivesfoundation.org - http://www.innocentlivesfoundation.org/ 04:39 - The Topic of the Day: Music and the Senses 06:20 - Subjective Taste 07:17 - Listen and Chill 09:54 - Beyond Your Expectations 12:26 - A Euphoric Sensation 14:11 - The Negative Side 15:24 - The Deeper Connection 17:17 - Understanding with MTV 19:40 - Moving Adverts 20:58 - Music Matters 24:35 - Synesthesia: An Overview 27:27 - Genius, Damaged or Both? 30:35 - Thinking Differently 33:47 - Finding What Works 34:59 - Music-Induced Analgesia 40:24 - Soothing the Savage Beast 41:56 - The Power of the Mind 42:49 - Benefits Package 43:35 - When We Were Young 46:57 - The Need to Be Seen 49:14 - Wrap Up 50:43 - Next Month: Trauma Bonding 51:07 - Outro -          www.social-engineer.com -          www.innocentlivesfoundation.org   Find us online: -          Twitter: https://twitter.com/abbiejmarono -          LinkedIn: linkedin.com/in/dr-abbie-maroño-phd-35ab2611a -          Instagram: @DoctorAbbieofficial -          Twitter: https://twitter.com/humanhacker -          LinkedIn: linkedin.com/in/christopherhadnagy   References: Bannister, S., & Eerola, T. (2023). Vigilance and social chills with music: Evidence for two types of musical chills. Psychology of Aesthetics, Creativity, and the Arts, 17(2), 242. Bragança, G. F. F., Fonseca, J. G. M., & Caramelli, P. (2015). Synesthesia and music perception. Dementia & neuropsychologia, 9, 16-23. Colver, M. C., & El-Alayli, A. (2016). Getting aesthetic chills from music: The connection between openness to experience and frisson. Psychology of Music, 44(3), 413-427. Dael, N., Smedt, T. D., & Paquier, P. F. (2012). Tasting music: A case of emotion-color synaesthesia. Neurocase, 18(2), 165-180. Hsieh C, Kong J, Kirsch I, Edwards RR, Jensen KB, Kaptchuk TJ, et al. Well-loved music robustly relieves pain: a randomized, controlled trial. PLoS ONE. (2014) 9:e107390. doi: 10.1371/journal.pone.0107390 Hubbard, E. M. (2007). Neurophysiology of synesthesia. Current psychiatry reports, 9(3), 193-199. Lombardi, R. (2011). The body, feelings, and the unheard music of the senses. Contemporary Psychoanalysis, 47(1), 3-24. Lunde, S. J., Vuust, P., Garza-Villarreal, E. A., Kirsch, I., Møller, A., & Vase, L. (2022). Music-induced analgesia in healthy participants is associated with expected pain levels but not opioid or dopamine-dependent mechanisms. Frontiers in Pain Research, 3, 734999. Powers, J. M., Ioachim, G., & Stroman, P. W. (2022). Music to my senses: Functional magnetic resonance imaging evidence of music analgesia across connectivity networks spanning the brain and brainstem. Frontiers in Pain Research, 3, 878258. Roy M, Peretz I, Rainville P. Emotional valence contributes to music-induced Analgesia. Pain. (2008) 134:140–7. doi: 10.1016/j.pain.2007.04.003 Smilek, D., Dixon, M. J., Cudahy, C., & Merikle, P. M. (2002). Synesthetic photisms influence visual perception. Journal of Cognitive Neuroscience, 14(8), 1057-1068 Spector, F., & Maurer, D. (2013). Synesthesia: a new approach to understanding the development of perception. Wang Y, Wei J, Guan X, Zhang Y, Zhang Y, Zhang N, et al. Music intervention in pain relief of cardiovascular patients in cardiac procedures: a systematic review and meta-analysis. Pain Med. (2020) 21:3055–65. doi: 10.1093/pm/pnaa148 Zamm, A., & Schlaug, G. (2015). Auditory-motor mapping training as an intervention to facilitate speech output in non-verbal children with autism: A proof of concept study. PLoS ONE, 10(6), e0129725.

  Hey there, welcome back to the Empowered Nutrition Podcast. I'm Erin Skinner, your host, and I'm excited to take you on a journey into the incredible world of Berberine in this episode. Together, we'll discover the superpowers of this natural plant compound and its profound impact on our digestive, metabolic, and hormonal health. Berberine: The Unsung Hero Imagine Berberine as the unsung hero of the supplement world. It's not a prescription drug, but it's gaining superstar status for its unique ability to kickstart the release of glucagon-like peptide-1 (GLP-1). These GLP-1 superpowers are a game-changer in the realm of metabolic health. Safety First: Navigating the Berberine Universe Let's navigate the safety of Berberine. Most adults can embrace its benefits, but we need to be cautious. Expect some minor side effects like mild abdominal discomfort, constipation, or the occasional bout of nausea. But a word of advice, Berberine is best suited for those facing health challenges. For healthy individuals, it may not be the supplement you're looking for. Witness Berberine's Breathtaking Feats Prepare to be wowed by Berberine's breathtaking feats. It swoops in to save the day in the battle against diabetes, polycystic ovary syndrome (PCOS), high cholesterol, and the formidable obesity villain. It's a powerful ally, but having healthcare professionals as your sidekicks when introducing Berberine to your health journey is a smart move. Dosing Drama and Cautious Calm Let's dive into the dosing drama. The script reads 500 milligrams, two to three times a day, for one to six months. Berberine may be a powerful ally, but long-term alliances should be approached with caution. Especially if your medication squad is already on standby. Berberine's Secret Weapons Discover Berberine's secret weapons as I unravel the six primary mechanisms through which it conquers the battlefield. From rallying nitrate-reducing bacteria to amping up short-chain fatty acid production, this hero doesn't back down. It's all part of the grand plan to reduce inflammation, optimize bile metabolism, foster Akkermansia bacteria growth, and control hormones to slay the dragons of appetite and sugar cravings. Calling All Health Warriors Berberine steps into the spotlight when health warriors face particular adversaries. When weight loss resistance, metabolic syndrome, insulin resistance, type 2 diabetes, and PCOS are the battlegrounds, Berberine is your trusty sword. For other quests, consult your healthcare professionals for guidance. Enduring Legacy The awe-inspiring aspect of Berberine? Its enduring legacy. Even after Berberine exits the stage, its impact on the gut microbiome continues to shine. It's like having a guardian angel looking out for your health, long after the final bow. The Final Act As we wrap up this episode, I hope you've gained a newfound appreciation for the superpowers of Berberine. This superhero in supplement form may be your ticket to a healthier, happier future. References used in this podcast episode: 1.The Natural Medicine's Database: Berberine (Professional Monograph) https://info.trchealthcare.com/natmed-ppc 2.Zhang Y, Gu Y, Ren H, et al. Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). Nat Commun. 2020;11(1):5015. 3.Habtemariam S. Berberine pharmacology and the gut microbiota: A hidden therapeutic link. Pharmacol Res. 2020;155:104722. 4.Zhang L, Wu X, Yang R, et al. Effects of Berberine on the Gastrointestinal Microbiota. Front Cell Infect Microbiol. 2020;10:588517. 5.Och A, Och M, Nowak R, Podgorska D, Podgorski R. Berberine, a Herbal Metabolite in the Metabolic Syndrome: The Risk Factors, Course, and Consequences of the Disease. Molecules. 2022;27(4). 6.Cao RY, Zheng Y, Zhang Y, et al. Berberine on the Prevention and Management of Cardiometabolic Disease: Clinical Applications and Mechanisms of Action. Am J Chin Med. 2021;49(7):1645-1666. 7.Wang H, Zhang H, Gao Z, Zhang Q, Gu C. The mechanism of berberine alleviating metabolic disorder based on gut microbiome. Front Cell Infect Microbiol. 2022;12:854885. 8.Li J, Meng P, Zhang J, He M. Effect of Berberine Hydrochloride on the Diversity of Intestinal Flora in Parkinson's Disease Patients. Contrast Media Mol Imaging. 2022;2022:8381870. 9.Ming J, Yu X, Xu X, et al. Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study. Genome Med. 2021;13(1):125. Ready to dive in? Listen here! Love it? Hate it? We'd love to hear your feedback!     Interested in our Lean for Life Membership? Heal your Metabolism with the Lean for Life app: https://empowered-nutrition.ck.page/193bb2cd67 Help yourself feel aligned using our three phase approach: Lean for Life Membership called Heal, Optimize , and Refinewhere you will be empowered to reverse previous metabolic damage with the assistance of our team of Registered Dietitian Nutritionists. Check out more details on our website!   Want to learn more about our one-on-one Empowered Nutrition coaching? Book a free chemistry call to discuss your story and see if we're a good fit. Enjoying the podcast? Please review the Empowered Nutrition Podcast on Apple Podcasts or wherever you listen! Then, send me a screenshot of your positive review to podcast@empowerednutrition.health as a DM on Instagram (@empowerednutrition.health).Include a brief description of what you're working on with your health and/or nutrition and I'll send you a free custom meal plan! Do you have questions you would like answered on the Empowered Nutrition podcast? You can propose your questions/ideas by email to: podcast@empowerednutrition.health Follow us on: Instagram | Facebook

En el episodio de hoy, profundizamos en el tema de la prevención de la gota y compartimos cinco acciones impactantes que puede tomar para reducir el riesgo de esta dolorosa afección. La gota, una forma de artritis, afecta a millones de personas en todo el mundo, pero al hacer algunos cambios simples en su estilo de vida, puede allanar el camino hacia un futuro más saludable. Únase a nosotros mientras descubrimos las acciones clave que pueden ayudarlo a prevenir la gota y adoptar una vida de mayor movilidad y bienestar. ¡Empecemos! Fuentes: Siqueira JH, Mill JG, Velasquez-Melendez G, et al. Los refrescos azucarados y el consumo de fructosa están asociados con la hiperuricemia: análisis transversal del Estudio Longitudinal Brasileño de Salud del Adulto (ELSA-Brasil). Nutrients. 2018;10(8):981. Zhang Y, Chen S, Yuan M, Xu Y, Xu H. Gota y dieta: una revisión completa de los mecanismos y la gestión.Nutrientes. 2022;14(17):3525. Juraschek SP, Gelber AC, Choi HK, Appel LJ, Miller ER 3er. Efectos de la dieta de enfoques dietéticos para detener la hipertensión (DASH) y la ingesta de sodio en el ácido úrico sérico.Artritis Reumatol. 2016;68(12):3002-3009. Atenuando el riesgo de mortalidad del ácido úrico sérico elevado: el papel de la actividad física infrautilizada.https://ard.bmj.com/content/74/11/2034.resumen

Gameplay and Game Design to Transform Learning - Laughter and Learning Outcomes in Medical Education (EP.22) With Michelle A. Nelsen, MS, HTL (ASCP) Incorporating games into your curriculum can be transformative. Games can be immersive and when constructed by learners, a game can move education from a passive endeavor to an active and engaging experience that promotes critical thinking teamwork experiential learning and empathy. Assistant Professor of Laboratory Medicine and Pathology and Program Director for the Mayo Clinic School of Health Sciences' Histology Technician Program, Michelle A. Nelsen, MS, HTL(ASCP), joins Stacy Craft to discuss concreate examples of leveraging the world of game design and gameplay to bring difficult content to life and build community in the virtual and in person classroom. Questions? Feedback? Ideas? Contact us at edufi@mayo.edu Additional Resources: Videos: Gamification in Higher Education | Christopher See | TEDxCUHK Articles: What does Game Based Learning Offer Higher Ed? Gonzaga University Game Design in the Classroom: 8 Steps to Get Started Xu M, Luo Y, Zhang Y, Xia R, Qian H, Zou X. Game-based learning in medical education. Front Public Health. 2023 Mar 3;11:1113682. doi: 10.3389/fpubh.2023.1113682. PMID: 36935696; PMCID: PMC10020233. Khanna A, Ravindran A, Ewing B, Zinnerstrom K, Grabowski C, Mishra A, Makdissi R. Escape MD: Using an Escape Room as a Gamified Educational and Skill-Building Teaching Tool for Internal Medicine Residents. Cureus. 2021 Sep 27;13(9):e18314. doi: 10.7759/cureus.18314. PMID: 34725586; PMCID: PMC8553278. Heim AB, Holt EA. From Bored Games to Board Games: Student-Driven Game Design in the Virtual Classroom. J Microbiol Biol Educ. 2021 Mar 31;22(1):22.1.19. doi: 10.1128/jmbe.v22i1.2323. PMID: 33884075; PMCID: PMC8012046. Powerpoint Presentation Games Templates

Dans ce nouvel épisode de Puls'In Vet, nous allons nous pencher sur l'effet de l'électro-acupuncture en cas de lésions de la muqueuse gastrique avec un article paru en 2022 dans Chinese Medicine , "NMR-based metabonomics reveals the dynamic effect of electro-acupuncture on central nervous system in gastric mucosal lesions (GML) rats". Cette étude utilise la résonnance magnétique nucléraire basée sur la métabolomique pour explorer les mécanismes de changement métabolique central lors de l'utilisation de l'électro-acupuncture. Les chercheurs ont ainsi pu mettre en évidence une probable interaction cerveau-estomac. Ces résultats offrent une nouvelle notre manière de prendre en charge les animaux souffrant de lésions de la muqueuse gastrique. Restez à l'écoute de Puls'In Vet pour en découvrir encore plus ! 

Date: February 27, 2023 Reference: Walsh PS, Schnadower D, Zhang Y, Ramgopal S, Shah SS, Wilson PM. Association of early oseltamivir with improved outcomes in hospitalized children with influenza, 2007-2020. JAMA Pediatr. 2022. Guest Skeptic: Dr. Marisu Rueda-Altez is a pediatric infectious disease fellow at Children's National Hospital in Washington, DC. She is also the […] The post SGEM #397: Give a Little Bit…of Oseltamivir to Pediatric Patients Admitted with Influenza first appeared on The Skeptics Guide to Emergency Medicine.

MedLink Neurology Podcast is delighted to feature selected episodes from BrainWaves, courtesy of James E Siegler MD, its originator and host. BrainWaves is an academic audio podcast whose mission is to educate medical providers through clinical cases and topical reviews in neurology, medicine, and the humanities, and episodes originally aired from 2016 to 2021. Originally released: August 17, 2017 This week's clinical case features Dr. Megha Dhamne, a neuromuscular fellow from the Cleveland Clinic. Two weeks ago, she reviewed some of the antibodies associated with autoimmune myositis. But what happens when you suspect an autoimmune myositis and antibody testing is negative? Produced by James E Siegler. Music by Chris Zabriski, The New Valleys, and Hyson. Voiceover by Tuyche Smrstik. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision-making. REFERENCES Choy EH, Isenberg DA. Treatment of dermatomyositis and polymyositis. Rheumatology (Oxford) 2002;41(1):7-13. PMID 11792873 Gordon PA, Winer JB, Hoogendijk JE, Choy EH. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2012;2012(8):CD003643. PMID 22895935 Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357(9250):96-100. PMID 11197446 Mammen A. Autoimmune muscle disease. Handb Clin Neurol 2016;133:467-84. PMID 27112692 Suresh E, Wimalaratna S. Proximal myopathy: diagnostic approach and initial management. Postgrad Med J 2013;89(1054):470-7. PMID 23596213  We believe that the principles expressed or implied in the podcast remain valid, but certain details may be superseded by evolving knowledge since the episode's original release date. 

Amidst the battle of the mental health crisis, major depressive disorder stands out as an all-too-common reality for many children and adolescents, but the forces of science and medicine can stand against this foe. Dr. Christopher Drescher, a clinical child psychologist, joins pediatric resident Dr. Daniel Allen and medical student Vuk Lacmanovic to remove the cape from this increasingly common condition and discuss its symptoms, diagnosis, and treatment. Specifically, they will: Define major depressive disorder (MDD) and recognize the common symptoms in both children and adolescents. Formulate a differential diagnosis for patients presenting with depressive symptoms. Recognize validated screening tools for depression in both children and adolescents. Review cognitive behavioral therapy and pharmacotherapy as treatment options. Review appropriate referral to a mental health specialist. Free CME Credit (requires sign-in): https://mcg.cloud-cme.com/course/courseoverview?P=0&EID=12493  References: Bhatia SK, Bhatia SC. Childhood and adolescent depression. Am Fam Physician. 2007 Jan 1;75(1):73-80. PMID: 17225707. Brent DA, Maalouf F. Depressive Disorders (in Childhood and Adolescence). In: Ebert MH, Leckman JF, Petrakis IL. eds. Current Diagnosis & Treatment: Psychiatry, 3e. McGraw-Hill; Accessed November 17, 2020. https://accessmedicine.mhmedical.com/content.aspx?bookid=2509§ionid=200807606 Clark MS, Jansen KL, Cloy JA. Treatment of childhood and adolescent depression. Am Fam Physician. 2012 Sep 1;86(5):442-8. PMID: 22963063. Fendrich M, Weissman MM, Warner V. Screening for depressive disorder in children and adolescents: validating the Center for Epidemiologic Studies Depression Scale for Children. Am J Epidemiol. 1990 Mar;131(3):538-51. doi: 10.1093/oxfordjournals.aje.a115529. PMID: 2301363. (PDF of CES-DC here) Forman-Hoffman V, McClure E, McKeeman J, Wood CT, Middleton JC, Skinner AC, Perrin EM, Viswanathan M. Screening for Major Depressive Disorder in Children and Adolescents: A Systematic Review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016 Mar 1;164(5):342-9. doi: 10.7326/M15-2259. Epub 2016 Feb 9. PMID: 26857836. Hathaway EE, Walkup JT, Strawn JR. Antidepressant Treatment Duration in Pediatric Depressive and Anxiety Disorders: How Long is Long Enough? Curr Probl Pediatr Adolesc Health Care. 2018 Feb;48(2):31-39. doi: 10.1016/j.cppeds.2017.12.002. Epub 2018 Jan 12. PMID: 29337001; PMCID: PMC5828899. March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry. 2007 Oct;64(10):1132-43. doi: 10.1001/archpsyc.64.10.1132. Erratum in: Arch Gen Psychiatry. 2008 Jan;65(1):101. PMID: 17909125. Meister R, Abbas M, Antel J, Peters T, Pan Y, Bingel U, Nestoriuc Y, Hebebrand J. Placebo response rates and potential modifiers in double-blind randomized controlled trials of second and newer generation antidepressants for major depressive disorder in children and adolescents: a systematic review and meta-regression analysis. Eur Child Adolesc Psychiatry. 2020 Mar;29(3):253-273. doi: 10.1007/s00787-018-1244-7. Epub 2018 Dec 8. PMID: 30535589; PMCID: PMC7056684. Rachel A. Zuckerbrot, Amy Cheung, Peter S. Jensen, Ruth E.K. Stein, Danielle Laraque and GLAD-PC STEERING GROUP. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part I. Practice Preparation, Identification, Assessment, and Initial Management. Pediatrics March 2018, 141 (3) e20174081; DOI: https://doi.org/10.1542/peds.2017-4081 Scott K, Lewis CC, Marti CN. Trajectories of Symptom Change in the Treatment for Adolescents With Depression Study. J Am Acad Child Adolesc Psychiatry. 2019 Mar;58(3):319-328. doi: 10.1016/j.jaac.2018.07.908. Epub 2019 Jan 8. PMID: 30768414; PMCID: PMC6557284. Sharma T, Guski LS, Freund N, Gøtzsche PC. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. BMJ. 2016 Jan 27;352:i65. doi: 10.1136/bmj.i65. PMID: 26819231; PMCID: PMC4729837. Siu AL; US Preventive Services Task Force. Screening for Depression in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. Pediatrics. 2016 Mar;137(3):e20154467. doi: 10.1542/peds.2015-4467. Epub 2016 Feb 8. PMID: 26908686. Weersing VR, Brent DA, Rozenman MS, Gonzalez A, Jeffreys M, Dickerson JF, Lynch FL, Porta G, Iyengar S. Brief Behavioral Therapy for Pediatric Anxiety and Depression in Primary Care: A Randomized Clinical Trial. JAMA Psychiatry. 2017 Jun 1;74(6):571-578. doi: 10.1001/jamapsychiatry.2017.0429. PMID: 28423145; PMCID: PMC5539834. Weersing VR, Shamseddeen W, Garber J, Hollon SD, Clarke GN, Beardslee WR, Gladstone TR, Lynch FL, Porta G, Iyengar S, Brent DA. Prevention of Depression in At-Risk Adolescents: Predictors and Moderators of Acute Effects. J Am Acad Child Adolesc Psychiatry. 2016 Mar;55(3):219-26. doi: 10.1016/j.jaac.2015.12.015. Epub 2016 Jan 18. PMID: 26903255; PMCID: PMC4783159. Xu Y, Bai SJ, Lan XH, Qin B, Huang T, Xie P. Randomized controlled trials of serotonin-norepinephrine reuptake inhibitor in treating major depressive disorder in children and adolescents: a meta-analysis of efficacy and acceptability. Braz J Med Biol Res. 2016 May 24;49(6):e4806. doi: 10.1590/1414-431X20164806. PMID: 27240293; PMCID: PMC4897997. Zhou X, Cipriani A, Zhang Y, Cuijpers P, Hetrick SE, Weisz JR, Pu J, Giovane CD, Furukawa TA, Barth J, Coghill D, Leucht S, Yang L, Ravindran AV, Xie P. Comparative efficacy and acceptability of antidepressants, psychological interventions, and their combination for depressive disorder in children and adolescents: protocol for a network meta-analysis. BMJ Open. 2017 Aug 11;7(8):e016608. doi: 10.1136/bmjopen-2017-016608. PMID: 28801423; PMCID: PMC5629731. Zhou X, Teng T, Zhang Y, Del Giovane C, Furukawa TA, Weisz JR, Li X, Cuijpers P, Coghill D, Xiang Y, Hetrick SE, Leucht S, Qin M, Barth J, Ravindran AV, Yang L, Curry J, Fan L, Silva SG, Cipriani A, Xie P. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2020 Jul;7(7):581-601. doi: 10.1016/S2215-0366(20)30137-1. PMID: 32563306; PMCID: PMC7303954.

CUPOM: BLACKFRIDAYGUIA www.tadeclinicagem.com.br/guia - Conheça o Guia TdC com 7 dias grátis Um serviço de revisão e atualização continuados em clínica médica. A informação que você precisa, do jeito que você prefere. Junte-se aos mais de 800 assinantes. Assine o Guia, ganhe tempo e atualize-se sem esforço. Joanne, Kaue e Lucca conversam sobre armadilhas no tromboembolismo pulmonar (TEP): Quando pedir d-dímero e ajuste, em que momento iniciar a anticoagulação, como fazer a estratificação, quando trombolisar, qual anticoagulante iniciar, anticoagular ou não o TEP subsegmentar/assintomático e um pouco de TEP na gestante. Referências: 1. Kahn SR, de Wit K. Pulmonary Embolism. N Engl J Med. 2022 Jul 7;387(1):45-57. doi: 10.1056/NEJMcp2116489. PMID: 35793208. 2. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Respir J 2019; 54. 3. Raja AS, Greenberg JO, Qaseem A, et al. Evaluation of Patients With Suspected Acute Pulmonary Embolism: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 2015; 163:701. 4. Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest 2021; 160:e545. 5. Kucher N, Goldhaber SZ. Management of massive pulmonary embolism. Circulation 2005; 112:e28. 6. Aujesky D, Obrosky DS, Stone RA, et al. A prediction rule to identify low-risk patients with pulmonary embolism. Arch Intern Med 2006; 166:169. 7. Becattini C, Casazza F, Forgione C, et al. Acute pulmonary embolism: external validation of an integrated risk stratification model. Chest 2013; 144:1539. 8. Righini M, Van Es J, Den Exter PL, Roy PM, Verschuren F, Ghuysen A, Rutschmann OT, Sanchez O, Jaffrelot M, Trinh-Duc A, Le Gall C, Moustafa F, Principe A, Van Houten AA, Ten Wolde M, Douma RA, Hazelaar G, Erkens PM, Van Kralingen KW, Grootenboers MJ, Durian MF, Cheung YW, Meyer G, Bounameaux H, Huisman MV, Kamphuisen PW, Le Gal G. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA. 2014 Mar 19;311(11):1117-24. doi: 10.1001/jama.2014.2135. Erratum in: JAMA. 2014 Apr 23-30;311(16):1694. PMID: 24643601. 9. Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A, Hutten BA, Jaff MR, Manja V, Schulman S, Thurston C, Vedantham S, Verhamme P, Witt DM, D Florez I, Izcovich A, Nieuwlaat R, Ross S, J Schünemann H, Wiercioch W, Zhang Y, Zhang Y. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020 Oct 13;4(19):4693-4738. doi: 10.1182/bloodadvances.2020001830. PMID: 33007077; PMCID: PMC7556153. 10. Duffett L, Castellucci LA, Forgie MA. Pulmonary embolism: update on management and controversies. BMJ. 2020 Aug 5;370:m2177. doi: 10.1136/bmj.m2177. PMID: 32759284. 11. van der Hulle T, Cheung WY, Kooij S, Beenen LFM, van Bemmel T, van Es J, Faber LM, Hazelaar GM, Heringhaus C, Hofstee H, Hovens MMC, Kaasjager KAH, van Klink RCJ, Kruip MJHA, Loeffen RF, Mairuhu ATA, Middeldorp S, Nijkeuter M, van der Pol LM, Schol-Gelok S, Ten Wolde M, Klok FA, Huisman MV; YEARS study group. Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study. Lancet. 2017 Jul 15;390(10091):289-297. doi: 10.1016/S0140-6736(17)30885-1. Epub 2017 May 23. Erratum in: Lancet. 2017 Jul 15;390(10091):230. PMID: 28549662.

Listen in as Dr. Nally discussed the history of gout, why Hippocrates only thought it happened to royalty and how you can treat and prevent it with a ketogenic or carnivorous lifestyle. Show Note Sources: Kanbara A., Seyama I. Effect of urine pH on uric acid excretion by manipulating food materials. Nucleosides, Nucleotides Nucleic Acids. 2011;30(12):1066–1071. Towiwat P., Li Z.G. The association of vitamin C, alcohol, coffee, tea, milk and yogurt with uric acid and gout. Int J Rheum Dis. 2015;18(5):495–501. Bedir A., Topbas M., Tanyeri F., Alvur M., Arik N. Leptin might be a regulator of serum uric acid concentrations in humans. Jpn Heart J. 2003;44(4):527–536. Garrod AB. The Nature and Treatment of Gout and Rheumatic Gout, 2nd ed, Walton and Maberly, London 1863. Dalbeth N, Phipps-Green A, Frampton C, et al. Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis. Ann Rheum Dis 2018; 77:1048. Hall AP, Barry PE, Dawber TR, McNamara PM. Epidemiology of gout and hyperuricemia. A long-term population study. Am J Med 1967; 42:27. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987; 82:421. Zalokar J, Lellouch J, Claude JR, Kuntz D. Epidemiology of serum uric acid and gout in Frenchmen. J Chronic Dis 1974; 27:59. BRILL JM, MCCARTY DJ. "STUDIES ON THE NATURE OF GOUTY TOPHI" BY MAX FREUDWEILER, 1899. (AN INFLAMMATORY RESPONSE TO INJECTED SODIUM URATE, 1899). AN ABRIDGED TRANSLATION, WITH COMMENTS. Ann Intern Med 1964; 60:486. McCarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med 1961; 54:452. Seegmiller JE, Howell RR, Malawista SE. The inflammatory reaction to sodium urate: its possible relationship to the genesis of acute gouty arthritis. JAMA 1962; 180:469. Hutton J, Fatima T, Major TJ, et al. Mediation analysis to understand genetic relationships between habitual coffee intake and gout. Arthritis Res Ther 2018; 20:135. Fanning N, Merriman TR, Dalbeth N, Stamp LK. An association of smoking with serum urate and gout: A health paradox. Semin Arthritis Rheum 2018; 47:825. Lin KC, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. J Rheumatol 2000; 27:1045. Zhang Y, Woods R, Chaisson CE, et al. Alcohol consumption as a trigger of recurrent gout attacks. Am J Med 2006; 119:800.e13. Hunter DJ, York M, Chaisson CE, et al. Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study. J Rheumatol 2006; 33:1341. Chhana A, Lee G, Dalbeth N. Factors influencing the crystallization of monosodium urate: a systematic literature review. BMC Musculoskelet Disord 2015; 16:296. Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum 1972; 15:189. Horvath SM, Hollander JL. INTRA-ARTICULAR TEMPERATURE AS A MEASURE OF JOINT REACTION. J Clin Invest 1949; 28:469. Martinon F, Pétrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440:237. Guerne PA, Terkeltaub R, Zuraw B, Lotz M. Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes. Arthritis Rheum 1989; 32:1443. Terkeltaub R, Zachariae C, Santoro D, et al. Monocyte-derived neutrophil chemotactic factor/interleukin-8 is a potential mediator of crystal-induced inflammation. Arthritis Rheum 1991; 34:894. di Giovine FS, Malawista SE, Thornton E, Duff GW. Urate crystals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial cells. Cytokine mRNA and protein kinetics, and cellular distribution. J Clin Invest 1991; 87:1375. Guerne PA, Terkeltaub R, Zuraw B, Lotz M. Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes. Arthritis Rheum 1989; 32:1443.

Management Service Organizations (MSOs) can help you delegate the business side of medicine so you can focus on patient care. Dr. MedLaw explains, including, how MSOs factor into the corporate practice of medicine and more.  Also, did you know cilia play an important role in early beginnings of cancer in neural crest cells? Lukas Sommer, PhD, discusses his teams' research in developmental and cell biology.Enjoy listening!https://www.anatomy.uzh.ch/en/research/sommer.htmlZingg D, Debbache J, Peña-Hernández R, Antunes AT, Schaefer SM, Cheng PF, Zimmerli D, Haeusel J, Calçada RR, Tuncer E, Zhang Y, Bossart R, Wong KK, Basler K, Dummer R, Santoro R, Levesque MP, Sommer L. EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation. Cancer Cell. 2018 Jul 9;34(1):69-84.e14. 

In this episode of the Epigenetics Podcast, we caught up with Goncalo Castelo-Branco from the Karolinska Institute to talk about his work on the characterization of epigenetic states in the Oligodendrocyte Lineage. The group from Gonçalo Castelo-Branco's lab focuses on characterizing epigenetic states of oligodendrocytes, with the aim to understand their contribution to diseases like multiple sclerosis. To do this the group used single-cell RNA-Seq to identify sub-populations of oligodendrocytes. Furthermore, the team pioneered improvements in CUT&Tag and applied it to the single-cell space, as well as developing spatial CUT&Tag. More recently they used nanobodies in an optimised version of single cell CUT&Tag that allows simultaneous probing of three epigenomic modalities at single-cell resolution, using nanobody-Tn5 fusion proteins. The three modalities encompass chromatin accessibility as measured via ATAC-Seq and two histone post-transcriptional modifications.   References Deng Y, Bartosovic M, Kukanja P, Zhang D, Liu Y, Su G, Enninful A, Bai Z, Castelo-Branco G, Fan R. Spatial-CUT&Tag: Spatially resolved chromatin modification profiling at the cellular level. Science. 2022 Feb 11;375(6581):681-686. doi: 10.1126/science.abg7216. Epub 2022 Feb 10. PMID: 35143307. Winick-Ng W, Kukalev A, Harabula I, Zea-Redondo L, Szabó D, Meijer M, Serebreni L, Zhang Y, Bianco S, Chiariello AM, Irastorza-Azcarate I, Thieme CJ, Sparks TM, Carvalho S, Fiorillo L, Musella F, Irani E, Torlai Triglia E, Kolodziejczyk AA, Abentung A, Apostolova G, Paul EJ, Franke V, Kempfer R, Akalin A, Teichmann SA, Dechant G, Ungless MA, Nicodemi M, Welch L, Castelo-Branco G, Pombo A. Cell-type specialization is encoded by specific chromatin topologies. Nature. 2021 Nov;599(7886):684-691. doi: 10.1038/s41586-021-04081-2. Epub 2021 Nov 17. PMID: 34789882; PMCID: PMC8612935. Bartosovic M, Kabbe M, Castelo-Branco G. Single-cell CUT&Tag profiles histone modifications and transcription factors in complex tissues. Nat Biotechnol. 2021 Jul;39(7):825-835. doi: 10.1038/s41587-021-00869-9. Epub 2021 Apr 12. PMID: 33846645; PMCID: PMC7611252. Marek Bartosovic, Gonçalo Castelo-Branco. Multimodal chromatin profiling using nanobody-based single-cell CUT&Tag. bioRxiv. 2022.03.08.483459; doi: https://doi.org/10.1101/2022.03.08.483459   Related Episodes Multiple challenges of CUT&Tag (Cassidee McDonough, Kyle Tanguay) Chromatin Profiling: From ChIP to CUT&RUN, CUT&Tag and CUTAC (Steven Henikoff)   Contact Active Motif on Twitter Epigenetics Podcast on Twitter Active Motif on LinkedIn Active Motif on Facebook Email: podcast@activemotif.com

Can the brain repair itself? Can it regenerate after damage? Will there be a full recovery after a brain injury?  I bring in a friend to talk about the latest advances in neuronal repair. In practice since 2001, Dr. Greg Eckel, co-founder of Nature's Cure clinic in Portland where he shares what he calls "Sarieah's gifts" with the world, has focused on chronic degenerative and neurodegenerative diseases for many years. Between the latest online fads and the crazy media headlines, it's easier more than ever to get confused about your health. If you want to make better decisions about your health so you can feel better and live longer, you've come to the right place. As a loving husband and clinician, he took a deep dive into medical research looking for cures to his wife's Creutzfeldt-Jakob disease, a rare, chronic neurodegenerative condition with no known cure. While he didn't find a solution for Sarieah, the information he discovered and now uses in his clinic is showing promise for thousands of people.    Key takeaways: [1:37] Introduction to Dr. Greg Eckel[2:24] Can the brain really regenerate?[6:11] What is the time frame for the brain to regenerate and what is the success rate?[7:20] VSEL's - Very Small Embryonic-Like Stem Cells[9:18] Main diseases' underlying categories for neurodegeneration - prion, auto-immune and traumatic brain injuries.[11:25] FAN-C approach - a framework that Dr. Eckel have created to evaluate, explore and develop a program for proper diagnosis.[12:43] How Dr. Eckel got into prionic activity.[14:00] Clinician's own grief as experience and inspiration to help people. [17:45] Getting your grief and emotions out.[24:27] What happens in the neurodegeneration FAN-C approach assessment?[25:15] Other causes of neurodegeneration[26:00] Why do proteins misfold? [26:50] The Braak's hypothesis of parkinson's disease[30:02] Homeodynamic regulation[32:14] Cellular regeneration - VSEL's[36:53] Hyperbaric oxygen - originally designed and developed for divers and helps heal the brain for regeneration.[39:41] Photobiomodulation - a light therapy using low level laser.[40:45] Acupuncture and Chinese medicine encourage proper blood flow and help the body and the brain heal.[42:56] Nature Cures Clinic and the Cloudhands and superbrain yoga videos.[43:35] Closing Topic references:   https://naturecuresclinic.com/brain-regeneration/   https://poddtoppen.se/podcast/1339733591/the-spectrum-of-health-with-dr-christine-schaffner/the-future-is-brain-regeneration-dr-greg-eckel-with-dr-christine-schaffner   https://pubmed.ncbi.nlm.nih.gov/28243222/   https://sitn.hms.harvard.edu/flash/2010/issue65/   https://www.nigms.nih.gov/education/fact-sheets/Pages/regeneration.aspx For more details about Dr. Greg Eckel, visit his website www.naturecuresclinic.com or join his exercises, QI gong and Super Brain yoga through www.naturecuresclinic.com/qigong. You can also book a consultation call with his team through naturecuresclinic.com/book-a-call.   Follow Dr. Greg Eckel on his social media accounts:Facebook: https://www.facebook.com/pg/NatureCuresClinic/posts/  Instagram: https://www.instagram.com/naturecurespdx/?hl=en LinkedIn: https://www.linkedin.com/in/drgregeckel/  Twitter: @drgreckel     HBOT and Brain health Resources:   “Hyperbaric Oxygen Alleviates Secondary Brain Injury After Trauma Through Inhibition of TLR4/NF-κB Signaling Pathway”. Meng XE, Zhang Y, Li N, Fan DF, Yang C, Li H, Guo DZ, Pan SY. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research. 2016 Jan 26; 22: 284-288 PMC [article] PMCID: PMC4734681, PMID: 26812205, DOI: 10.12659/MSM.894148 Boussi-Gross R, Golan H, Fishlev G, Bechor Y, Volkov O, Bergan J, Friedman M, Hoofien D, Shlamkovitch N, Ben-Jacob E, Efrati S. “Hyperbaric oxygen therapy can improve post concussion syndrome years after mild traumatic brain injury - randomized prospective trial”. PLoS One. 2013 Nov 15;8(11):e79995. doi: 10.1371/journal.pone.0079995. eCollection 2013. PubMed [citation] PMID: 24260334, PMCID: PMC3829860 Thom SR, Bhopale VM, Velazquez OC, Goldstein LJ, Thom LH, Buerk DG. “Stem cell mobilization by hyperbaric oxygen”. Am J Physiol Heart Circ Physiol. 2006 Apr;290(4):H1378-86. Epub 2005 Nov 18. PubMed [citation] PMID: 16299259 “ROS and Brain Diseases: The Good, the Bad, and the Ugly”. Popa-Wagner A, Mitran S, Sivanesan S, Chang E, Buga AM. “Oxidative Medicine and Cellular Longevity”. 2013 Dec 5; 2013: 963520 PMC [article] PMCID: PMC3871919, PMID: 24381719, DOI: 10.1155/2013/963520 “Hyperbaric oxygen therapy promotes neurogenesis: where do we stand?”. Mu J, Krafft PR, Zhang JH. Medical Gas Research. 2011 Jun 27; 1: 14 PMC [article] PMCID: PMC3231808, PMID: 22146131, DOI: 10.1186/2045-9912-1-14   PARKINSONS REFERENCES:  (etiology, causes, treatments)   “d-β-Hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's Disease”. Kashiwaya Y, Takeshima T, Mori N, Nakashima K, Clarke K, Veech RL. Proceedings of the National Academy of Sciences of the United States of America. 2000 May 9; 97(10): 5440-5444 PMC [article] PMCID: PMC25847, PMID: 10805800, DOI: 10.1073/pnas.97.10.5440 Han L, Xie YH, Wu R, Chen C, Zhang Y, Wang XP. “Traditional Chinese medicine for modern treatment of Parkinson's disease”. Chin J Integr Med. 2017 Aug;23(8):635-640. doi: 10.1007/s11655-016-2537-7. Epub 2017 Jan 20. Review. PubMed [citation] PMID: 28108911 Karlsson O, Lindquist NG. “Melanin affinity and its possible role in neurodegeneration”. J Neural Transm (Vienna). 2013 Dec;120(12):1623-30. doi: 10.1007/s00702-013-1062-5. Epub 2013 Jul 3. Review. PubMed [citation] PMID: 23821370 “Therapeutic potential of autophagy-enhancing agents in Parkinson's disease”. Moors TE, Hoozemans JJ, Ingrassia A, Beccari T, Parnetti L, Chartier-Harlin MC, van de Berg WD. Molecular Neurodegeneration. 2017 Jan 25; 12: 11 PMC [article] PMCID: PMC5267440, PMID: 28122627, DOI: 10.1186/s13024-017-0154-3 Goldman SM. “Environmental toxins and Parkinson's disease”. Annu Rev Pharmacol Toxicol. 2014;54:141-64. doi: 10.1146/annurev-pharmtox-011613-135937. Epub 2013 Sep 16. Review. PubMed [citation] PMID: 24050700 Agim ZS, Cannon JR. “Dietary factors in the etiology of Parkinson's disease”. Biomed Res Int. 2015;2015:672838. doi: 10.1155/2015/672838. Epub 2015 Jan 20. Review. PubMed [citation] PMID: 25688361, PMCID: PMC4320877 Montgomery EB Jr. “Heavy metals and the etiology of Parkinson's disease and other movement disorders”. Toxicology. 1995 Mar 31;97(1-3):3-9. Review. PubMed [citation] PMID: 7716790 Ward RJ, Dexter DT, Crichton RR. “Chelating agents for neurodegenerative diseases”. Curr Med Chem. 2012;19(17):2760-72. Review. PubMed [citation] PMID: 22489724 Hozumi I, Hasegawa T, Honda A, Ozawa K, Hayashi Y, Hashimoto K, Yamada M, Koumura A, Sakurai T, Kimura A, Tanaka Y, Satoh M, Inuzuka T. “Patterns of levels of biological metals in CSF differ among neurodegenerative diseases”. J Neurol Sci. 2011 Apr 15;303(1-2):95-9. doi: 10.1016/j.jns.2011.01.003. Epub 2011 Feb 2. PubMed [citation] PMID: 21292280 Chu Y, Kordower JH. “The prion hypothesis of Parkinson's disease”. Curr Neurol Neurosci Rep. 2015 May;15(5):28. doi: 10.1007/s11910-015-0549-x. PubMed [citation] PMID: 25868519   What did you learn about today's topic? Let us know by leaving a review! Visit these links to learn more: https://www.drchristianson.com/ Dr. Christianson on Facebook (http://www.facebook.com/DrAlanChristianson/) Dr. Christianson on Instagram (http://www.instagram.com/dralanchristianson/) Subscribe for more Medical Myths, Legends, & Fairytales: Apple Podcasts (https://podcasts.apple.com/us/podcast/medical-myths-legends-fairytales/id1467232418) Spotify (https://open.spotify.com/show/0HaZ75TpOCazsRQSG0AOFs) YouTube (https://www.youtube.com/user/Alannmd/videos)

Dr. James Cox explains an underdiagnosed cause of lower back pain called Bertolotti's syndrome and how it can be effectively treated with Cox Technic. Dr. Cox is the developer of Cox® Technic Flexion Distraction Manipulation and the proud participant in the on-going federal research projects involving the National University of Health Sciences, Palmer College of Chiropractic Research Center, Loyola Stritch School of Medicine, University of Illinois, University of Iowa, Auburn University, Keiser University, etc. He is a member of the postgraduate faculty of the National University of Health Sciences and has been privileged to speak throughout the world. Resources: About Dr. Cox curriculum vitae  link to info on supplements:  Cox Technic Resource Center Inc Discat Plus Enhanced specifically Discat & Joint Pain Relief specifically Find a Back Doctor The Cox 8 Table by Haven Medical References: Cox JM. Low Back Pain: Mechanism, Diagnosis, Treatment. 7th ed. Lippincott Williams & Wilkins, 2011, Chapter 12, “Transitional Segment.” Pages 578-588 Keim HA, Kirkaldy Willis WH. “Low Back Pain.” CIBA: Clinical Symposia, 1980;32(6). Crane J, Cragon R, O'Neill J, Berger AA, Kassem H, Sherman WF, Paladini A, Varrassi G, Odisho AS, Miriyala S, Kaye AD. A Comprehensive Update of the Treatment and Management of Bertolotti's Syndrome: A Best Practices Review. Orthop Rev (Pavia). 2021 Jun 22;13(2):24980. doi: 10.52965/001c.24980. PMID: 34745474; PMCID: PMC8567758. Jin L, Yin Y, Chen W, Zhang R, Guo J, Tao S, Guo Z, Hou Z, Zhang Y. Role of the Lumbosacral Transition Vertebra and Vertebral Lamina in the Pathogenesis of Lumbar Disc Herniation. Orthop Surg. 2021 Dec;13(8):2355-2362. doi: 10.1111/os.13122. Epub 2021 Nov 17. PMID: 34791784. Vadera S: Castellvi classification of lumbosacral transitional vertebrae. https://radiopaedia.org/articles/castellvi-classification-of-lumbosacral-transitional-vertebrae. Sourced on 12/11/21 Kawtharani S, Bsat SA, El Housheimy M, Moussalem C, Halaoui A, Sunna T. A case of Bertolotti's syndrome as a cause of sciatica. Surg Neurol Int. 2021 Oct 11;12:516. doi: 10.25259/SNI_756_2021. PMID: 34754566; PMCID: PMC8571205. Hanhivaara J, Määttä JH, Karppinen J, Niinimäki J, Nevalainen MT. The Association of Lumbosacral Transitional Vertebrae with Low Back Pain and Lumbar Degenerative Findings in MRI: A Large Cohort Study. Spine (Phila Pa 1976). 2022 Jan 15;47(2):153-162. doi: 10.1097/BRS.0000000000004244. PMID: 34610612. Sun J, Chhabra A, Thakur U, Vazquez L, Xi Y, Wells J. The association of lumbosacral transitional vertebral anomalies with acetabular dysplasia in adult patients with hip-spine syndrome : a cross-sectional evaluation of a prospective hip registry cohort. Bone Joint J. 2021 Aug;103-B(8):1351-1357. doi: 10.1302/0301-620X.103B8.BJJ-2020-2481.R1. PMID: 34334048. Watanabe K, Mitsui K, Sasaki J, Kumaki D. Subacute hemorrhagic cyst of the ligamentum flavum occurred in the lumbosacral transitional vertebra presenting as progressive lumbar nerve root compression: a case report. J Spine Surg. 2021 Jun;7(2):238-243. doi: 10.21037/jss-20-683. PMID: 34296039; PMCID: PMC8261570. Tatara Y, Niimura T, Sekiya T, Mihara H. Changes in Lumbosacral Anatomy and Vertebral Numbering in Patients with Thoracolumbar and/or Lumbosacral Transitional Vertebrae. JB JS Open Access. 2021 Jul 14;6(3):e20.00167. doi: 10.2106/JBJS.OA.20.00167. PMID: 34278183; PMCID: PMC8280013. Sugiura K, Morimoto M, Higashino K, Takeuchi M, Manabe A, Takao S, Maeda T, Sairyo K. Transitional vertebrae and numerical variants of the spine : prevalence and relationship to low back pain or degenerative spondylolisthesis. Bone Joint J. 2021 Jul;103-B(7):1301-1308. doi: 10.1302/0301-620X.103B7.BJJ-2020-1760.R1. PMID: 34192932. Gluding D, Stock KF, Tellhelm B, Kramer M, Eley N. Genetic background of lumbosacral transitional vertebrae in German shepherd dogs. J Small Anim Pract. 2021 Nov;62(11):967-972. doi: 10.1111/jsap.13380. Epub 2021 Jun 21. PMID: 34155659. Okamoto M, Hasegawa K, Hatsushikano S, Kobayashi K, Sakamoto M, Ohashi M, Watanabe K. Influence of lumbosacral transitional vertebrae on spinopelvic parameters using biplanar slot scanning full body stereoradiography-analysis of 291 healthy volunteers. J Orthop Sci. 2021 May 6:S0949-2658(21)00126-3. doi: 10.1016/j.jos.2021.03.009. Epub ahead of print. PMID: 33966957. Garg B, Mehta N, Goyal A, Rangaswamy N, Upadhayay A. Variations in the Number of Thoracic and Lumbar Vertebrae in Patients With Adolescent Idiopathic Scoliosis: A Retrospective, Observational Study. Int J Spine Surg. 2021 Apr;15(2):359-367. doi: 10.14444/8047. Epub 2021 Apr 1. PMID: 33900995; PMCID: PMC8059404. Shinonara K, Kaneko M, Ugawa R, Arataki S, Takeuchi K. The effectiveness of preoperative assessment using a patient-specific three-dimensional pseudoarticulation model for minimally invasive posterior resection in a patient with Bertolotti's syndrome: a case report. J Med Case Rep. 2021 Feb 16;15(1):68. doi: 10.1186/s13256-020-02635-y. PMID: 33588921; PMCID: PMC7885622. Becker L, Ziegeler K, Diekhoff T, Palmowski Y, Pumberger M, Schömig F. Musculature adaption in patients with lumbosacral transitional vertebrae: a matched-pair analysis of 46 patients. Skeletal Radiol. 2021 Aug;50(8):1697-1704. doi: 10.1007/s00256-021-03722-x. Epub 2021 Feb 3. PMID: 33533964; PMCID: PMC8208907. Haffer H, Becker L, Putzier M, Wiethölter M, Ziegeler K, Diekhoff T, Pumberger M, Hardt S. Changes of Fixed Anatomical Spinopelvic Parameter in Patients with Lumbosacral Transitional Vertebrae: A Matched Pair Analysis. Diagnostics (Basel). 2021 Jan 2;11(1):59. doi: 10.3390/diagnostics11010059. PMID: 33401698; PMCID: PMC7824527. Luo R, Barsoum D, Ashraf H, Cheng J, Hurwitz NR, Goldsmith CY, Moley PJ. Prevalence of Lumbosacral Transitional Vertebrae in Patients With Symptomatic Femoroacetabular Impingement Requiring Hip Arthroscopy. Arthroscopy. 2021 Jan;37(1):149-155. doi: 10.1016/j.arthro.2020.08.034. Epub 2020 Sep 10. PMID: 32919025; PMCID: PMC8177691. Johnson ZD, Aoun SG, Ban VS, El Ahmadieh TY, Kafka B, Wolfe C, Adogwa O, Bagley CA, Tamimi MA. Bertolotti Syndrome With Articulated L5 Transverse Process Causing Intractable Back Pain: Surgical Video Showcasing a Minimally Invasive Approach for Disconnection: 2-Dimensional Operative Video. Oper Neurosurg (Hagerstown). 2021 Feb 16;20(3):E219-E220. doi: 10.1093/ons/opaa343. PMID: 33294931. Dhanjani S, Altaleb M, Margalit A, Puvanesarajah V, Jain A. Pediatric Back Pain Associated with Bertolotti Syndrome: A Report of 3 Cases with Varying Treatment Strategies. JBJS Case Connect. 2021 Nov 17;11(4). doi: 10.2106/JBJS.CC.21.00068. PMID: 34788257.

ترتبط كلمة الإدمان بالعديد من الأمور؛ الألعاب الرقمية، واستخدام الهاتف ومواقع التواصل الاجتماعي، وغيرها. لكن هل سبق وسمعتم عن الإدمان على الحب؟ ترى، ما هي مضاره على الإنسان؟ هذه الحلقة من بحث وكتابة بشر النجار، وتحرير عمر فارس، ومونتاج محمود أبو ندى، وتدقيق تالا مراغه، وتقديم سلام قطناني. في بودكاست «معلوم» تُبسّط سلام قطناني العلوم للإجابة على أسئلة هامّة عن أنفسنا والعالم والكون. بودكاست «معلوم» من إنتاج «صوت». بودكاست «معلوم» من إنتاج «صوت». المصادر: - de Boer A, van Buel EM, Ter Horst GJ. Love is more than just a kiss: A neurobiological perspective on love and affection. Neuroscience. 2012;201:114-124. - Klein MO, Battagello DS, Cardoso AR, Hauser DN, Bittencourt JC, Correa RG. Dopamine: Functions, signaling, and association with neurological diseases. Cell Mol Neurobiol. 2019;39(1):31-59. - Berger M, Gray JA, Roth BL. The expanded biology of serotonin. Annu Rev Med. 2009;60:355-366. - Carter CS. The oxytocin-vasopressin pathway in the context of love and fear. Frontiers in endocrinology. 2017;8:356. - Zou Z, Song H, Zhang Y, Zhang X. Romantic love vs. drug addiction may inspire a new treatment for addiction. Frontiers in psychology. 2016;7:1436. - Earp BD, Wudarczyk OA, Foddy B, Savulescu J. Addicted to love: What is love addiction and when should it be treated? Philosophy, psychiatry, & psychology : PPP. 2017;24(1):77-92. Support the show: https://www.sowt.com/plus

Jonathan interviews Dr. Kim Noels - Professor, Faculty of Arts - Psychology Department at the University of Alberta. academia.edu Google Scholar Contacts: JonathanShachter@gmail.com, LostInCitations@gmail.com

Dr. Tony Anderson, an anesthesiologist at the Stanford University School of Medicine, joins us to discuss the evolving literature and evidence around perioperative management of buprenorphine. Special thanks to Dr. Ashwini Joshi for her assistance with researching for the episode.  Thanks for listening! If you enjoy our content, leave a 5-star review on Apple Podcasts and consider helping us offset the costs of production by donating through our Patreon at https://bit.ly/3n0sklh. — Follow us on Instagram @DepthofAnesthesia and on Twitter @DepthAnesthesia for podcast and literature updates. Email us at depthofanesthesia@gmail.com with episode ideas or if you'd like to join our team. Music by Stephen Campbell, MD. — References Anderson TA, Quaye ANA, Ward EN, Wilens TE, Hilliard PE, Brummett CM. To Stop or Not, That Is the Question: Acute Pain Management for the Patient on Chronic Buprenorphine. Anesthesiology. 2017 Jun;126(6):1180-1186. doi: 10.1097/ALN.0000000000001633. PMID: 28511196; PMCID: PMC7041233. Goel A, Azargive S, Lamba W, Bordman J, Englesakis M, Srikandarajah S, Ladha K, Di Renna T, Shanthanna H, Duggan S, Peng P, Hanlon J, Clarke H. The perioperative patient on buprenorphine: a systematic review of perioperative management strategies and patient outcomes. Can J Anaesth. 2019 Feb;66(2):201-217. English. doi: 10.1007/s12630-018-1255-3. Epub 2018 Nov 27. PMID: 30484167. Goel A, Azargive S, Weissman JS, Shanthanna H, Hanlon JG, Samman B, Dominicis M, Ladha KS, Lamba W, Duggan S, Di Renna T, Peng P, Wong C, Sinha A, Eipe N, Martell D, Intrater H, MacDougall P, Kwofie K, St-Jean M, Rashiq S, Van Camp K, Flamer D, Satok-Wolman M, Clarke H. Perioperative Pain and Addiction Interdisciplinary Network (PAIN) clinical practice advisory for perioperative management of buprenorphine: results of a modified Delphi process. Br J Anaesth. 2019 Aug;123(2):e333-e342. doi: 10.1016/j.bja.2019.03.044. Epub 2019 May 29. PMID: 31153631; PMCID: PMC6676043. Hansen LE, Stone GE, Matson CA, Tybor DJ, Pevear ME, Smith EL. Total joint arthroplasty in patients taking methadone or buprenorphine/naloxone preoperatively for prior heroin addiction: a prospective matched cohort study. J Arthroplasty 2016; 31: 1698-701. (29) Höflich AS, Langer M, Jagsch R, Bäwert A, Winklbaur B, Fischer G, Unger A. Peripartum pain management in opioid dependent women. Eur J Pain. 2012 Apr;16(4):574-84. doi: 10.1016/j.ejpain.2011.08.008. PMID: 22396085; PMCID: PMC3290684. Li A, Schmiesing C, Aggarwal AK.Evidence for Continuing Buprenorphine in the Perioperative Period. Clin J Pain. 2020 Oct; 36(10): 764-774.doi: 10.1097/AJP.0000000000000858. PMID: 32520814 Macintyre PE, Russel RA, Usher KA, Gaughwin M, Huxtable CA. Pain relief and opioid requirements in the first 24 hours after surgery in patients taking buprenorphine and methadone opioid substitution therapy. Anaesth Intensive Care 2013; 41: 222-30 (27) Meyer M, Paranya G, Keefer Norris A, Howard D. Intrapartum and postpartum analgesia for women maintained on buprenorphine during pregnancy. Eur J Pain. 2010 Oct;14(9):939-43. doi: 10.1016/j.ejpain.2010.03.002. Epub 2010 May 4. PMID: 20444630. Quaye A, Potter K, Roth S, Acampora G, Mao J, Zhang Y. Perioperative Continuation of Buprenorphine at Low-Moderate Doses Was Associated with Lower Postoperative Pain Scores and Decreased Outpatient Opioid Dispensing Compared with Buprenorphine Discontinuation. Pain Med. 2020 Sep 1;21(9):1955-1960. doi: 10.1093/pm/pnaa020. PMID: 32167541.

Referências:1.Alizai H, Walter W, Khodarahmi I, Burke CJ. Cartilage Imaging in Osteoarthritis. Semin Musculoskelet Radiol. 2019; 23 (5): 569-78.2.Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019; 393 (10182): 1745-59.3.Roemer FW, Crema MD, Trattnig S, Guermazi A. Advances in imaging of osteoarthritis and cartilage. Radiology. 2011; 260 (2): 332-54.4.Mcgonagle D, Tan AL, Grainger AJ, Benjamim M. Heberden's nodes and what Heberden could not see: the pivotal role of ligaments in the pathogenesis of early nodal osteoarthritis and beyond. Rheumatology 2008; 47: 1278–12855.Sophia Fox AJ, Bedi A, Rodeo SA. The basic science of articular cartilage: structure, composition, and function. Sports Health. 2009; 1 (6): 461-8.6.Pathria MN, Chung CB, Resnick DL. Acute and Stress-related Injuries of Bone and Cartilage: Pertinent Anatomy, Basic Biomechanics, and Imaging Perspective. Radiology 2016; 280 (1): 21-38.7.Huber M, Trattnig S, Lintner F. Anatomy, biochemistry, and physiology of articular cartilage. Invest Radiol. 2000; 35 (10): 573-80.8.Heijink A, Gomoll AH, Madry H, Drobnic M, Filardo G, Espregueira-Mendes J et al. Biomechanical Considerations in the Pathogenesis of Osteoarthritis of the Knee. Knee Surg Sports Traumatol Arthrosc 2012; 20: 423-4359.Martinez-Moreno D, Jimenez G, Galvez-Martin P, Rus G, Marchal JA. Cartilage biomechanics: A key factor for osteoarthritis regenerative medicine. Biochim Biophys Acta Mol Basis Dis. 2019; 1865 (6): 1067-75.10.Wang X, Hunter DJ, Jin X, Ding C. The importance of synovial inflammation in osteoarthritis: current evidence from imaging assessments and clinical trials. Osteoarthritis and Cartilage 2018; 26 (2): 165e17411.Haugen IK, Boyesen P. Imaging modalities in hand osteoarthritis – status and perspectives of conventional radiography, magnetic resonance imaging, and ultrasonography. Arthritis Res Ther 2011; 13 (6): 24812.Ridley WE, Xiang H, Han J, Ridley LJ. Gull-wing Deformity: Osteoarthritis. J Med Im Rad Onc 2018; 62 (S1): 141.13.Zhang Y, Niu J, Kelly-Hayes M, Chaisson CE, Aliabadi P, Felson DT. Prevalence of symptomatic hand osteoarthritis and its impact on functional status among the elderly: The Framingham Study. Am J Epidemiol. 2002; 156 (11): 1021-7.14.N S. Hand Osteoarthritis — Clinical Presentation, Phenotypes and Management. 2015.15.Tan AL, Grainger AJ, Tanner SF, Shelley DM, Pease C, Emery P, et al. High-resolution magnetic resonance imaging for the assessment of hand osteoarthritis. Arthritis Rheum. 2005; 52 (8): 2355-65.16.Mathiessen A, Slatkowsky-Christensen B, Kvien TK, Hammer HB, Haugen IK. Ultrasound-detected inflammation predicts radiographic progression in hand osteoarthritis after 5 years. Ann Rheum Dis. 2016; 75 (5): 825-30.17.Okano T, Mamoto K, Di Carlo M, Salaffi F. Clinical utility and potential of ultrasound in osteoarthritis. Radiol Med. 2019; 124 (11): 1101-11.18.Hammer HB, Iagnocco A, Mathiessen A, Filippucci E, Gandjbakhch F, Kortekaas MC, et al. Global ultrasound assessment of structural lesions in osteoarthritis: a reliability study by the OMERACT ultrasonography group on scoring cartilage and osteophytes in finger joints. Ann Rheum Dis. 2016; 75 (2): 402-7.

@fabiodominski Fonte: Zhao Y, Hu F, Feng Y, Yang X, Li Y, Guo C, Li Q, Tian G, Qie R, Han M, Huang S, Wu X, Zhang Y, Wu Y, Liu D, Zhang D, Cheng C, Zhang M, Yang Y, Shi X, Lu J, Hu D. Association of Cycling with Risk of All-Cause and Cardiovascular Disease Mortality: A Systematic Review and Dose-Response Meta-analysis of Prospective Cohort Studies. Sports Med. 2021 Cepeda, M., Schoufour, J., Freak-Poli, R., Koolhaas, C. M., Dhana, K., Bramer, W. M., & Franco, O. H. (2017). Levels of ambient air pollution according to mode of transport: a systematic review. The Lancet Public Health, 2(1), e23-e34. Tainio, M., de Nazelle, A. J., Götschi, T., Kahlmeier, S., Rojas-Rueda, D., Nieuwenhuijsen, M. J., ... & Woodcock, J. (2016). Can air pollution negate the health benefits of cycling and walking?. Preventive medicine, 87, 233-236. De Hartog, J. J., Boogaard, H., Nijland, H., & Hoek, G. (2010). Do the health benefits of cycling outweigh the risks?. Environmental health perspectives, 118(8), 1109-1116. Alessio, Helaine M.1; Reiman, Timothy1; Kemper, Brett1; von Carlowitz, Winston1; Bailer, A. John2; Timmerman, Kyle L.1 Metabolic and Cardiovascular Responses to a Simulated Commute on an E-Bike, Translational Journal of the ACSM: Spring 2021 --- Support this podcast: https://anchor.fm/fabio-dominski/support

In this new episode we will be discussing with Dr. Fernando Exposto, DDS, MSc, PhD about muscle pain and pain referral. Dr. Fernando Exposto is currently a Postdoctoral Fellow and Clinical Instructor at Aarhus University in Denmark. He obtained his PhD degree in Health Sciences at the same university in 2019. He graduate from dental school at ISCSEM in Lisbon (Portugal)in 2007. He completed a Master in Dental Sciences, Danube University (Austria) from 2007 to 2011. In 2015, he graduated from the 2 year CODA approved program in Orofacial Pain at the University of Kentucky (USA). From 2016 to 2018 he completed a Master in Headache Disorders at the Copenhagen University (Denmark). Dr. Exposto is a Diplomate by the American Board of Orofacial Pain since 2016. References: Comparison of masseter muscle referred sensations after mechanical and glutamate stimulation: a randomized, double-blind, controlled, cross-over study. / Exposto, Fernando; Udagawa, Gen; Naganawa, Takuya; Svensson, Peter. In: Pain, Vol. 159, No. 12, 01.12.2018, p. 2649-2657. Comparison of Pain-Generated Functional Outcomes in Experimental Models of Delayed-Onset Muscle Soreness and Nerve Growth Factor Injection of the Masticatory Muscles./ Zhang Y, Exposto FG, Grigoriadis A, Lobbezoo F, Koutris M, Zhang J, et al. Journal of oral & facial pain and headache [Internet]. 2020 Sep [cited 2021 Feb 13];34(4):311–22. Further evidence for overlaps among chronic pain conditions : But no news about causal relationships. / Svensson, Peter; Exposto, Fernando. In: Journal of Oral and Facial Pain and Headache, Vol. 34, No. Suppl., 2020, p. s6-s8.

FDA 连续批准2个针对MET外显子突变的非小细胞肺癌的靶向药NEJM 关于电子烟相关急性肺损伤的住院与死亡的报告Nature 抑制淋巴毒素β受体可诱导肺再生卡马替尼（capmatinib）在非小细胞肺癌患者中，MET外显子14跳跃突变发生在3~4%、MET扩增发生率1~6%。卡马替尼是一种选择性的MET受体抑制剂，在具有不同类型MET激活的癌症模型中显示出活性。2020年5月，FDA批准卡马替尼用于MET外显子14跳跃突变的非小细胞肺癌的一线治疗。《GEOMETRY mono-1研究：卡马替尼治疗MET外显子14突变或MET扩增的非小细胞肺癌的2期临床研究》New England Journal of Medicine，2020年9月 (1)参与者为364名晚期非小细胞肺癌患者，根据既往治疗和MET状态分组，接受卡马替尼治疗。其中MET外显子14跳跃突变的患者中，曾接受过治疗的整体缓解率41%，未接受过治疗的缓解率68%，中位缓解时间分别为9.7个月和12.6个月。在MET扩增的患者中，疗效有限。MET基因拷贝数

FDA 连续批准2个针对MET外显子突变的非小细胞肺癌的靶向药NEJM 关于电子烟相关急性肺损伤的住院与死亡的报告Nature 抑制淋巴毒素β受体可诱导肺再生卡马替尼（capmatinib）在非小细胞肺癌患者中，MET外显子14跳跃突变发生在3~4%、MET扩增发生率1~6%。卡马替尼是一种选择性的MET受体抑制剂，在具有不同类型MET激活的癌症模型中显示出活性。2020年5月，FDA批准卡马替尼用于MET外显子14跳跃突变的非小细胞肺癌的一线治疗。《GEOMETRY mono-1研究：卡马替尼治疗MET外显子14突变或MET扩增的非小细胞肺癌的2期临床研究》New England Journal of Medicine，2020年9月 (1)参与者为364名晚期非小细胞肺癌患者，根据既往治疗和MET状态分组，接受卡马替尼治疗。其中MET外显子14跳跃突变的患者中，曾接受过治疗的整体缓解率41%，未接受过治疗的缓解率68%，中位缓解时间分别为9.7个月和12.6个月。在MET扩增的患者中，疗效有限。MET基因拷贝数

FDA 批准卡那单抗用于治疗成人Still病Lancet 苏金单抗与阿达木单抗治疗银屑病关节炎的头对头比较Arthri & Rheumatol重组腺苷脱氨酶可改善系统性硬化症模型的纤维化卡那单抗（canakinumab）上周一的心脏科专题中，我们聊到了冠心病的抗炎治疗最新进展，目前研究热点集中在IL-1β单克隆抗体卡那单抗和秋水仙碱。今天我们来聊一聊卡那单抗在免疫科中的应用。卡那单抗（canakinumab）最初于2009年被FDA批准用于治疗Cryopyrin相关周期性综合征（CAPS）、全身型幼年特发性关节炎以及三种少见的周期性发热综合征；2020年6月，卡那单抗被FDA批准用于治疗成人Still病。《卡那单抗用于治疗成人Still病以减少关节炎的表现：2期临床试验》Annals of Rheumatic Diseases，2020年8月 (1)这项多中心、双盲、随机、安慰剂对照试验，旨在评价其治疗成人Still病的有效性和安全性。研究纳入19名多关节受累的成人Still病患者，随机给予卡那单抗和安慰剂治疗。基线时，卡那单抗组和安慰剂组的平均疾病活动评分为5.4和5.3。在卡那单抗组中，61%的患者达到30%应答率，50%的患者达到50%应答率，28%的患者达到70%应答率；而对照组仅为20%、6.7%和0%（p=0.033，0.009和0.049)。卡那单抗组的两名患者经历了严重的不良事件。结论：卡那单抗治疗可改善多项成人Still病的疗效指标。银屑病性关节炎银屑病关节炎（psoriatic arthritis，PsA）是一种与银屑病有关的炎症性肌肉骨骼疾病。主要表现为受累关节疼痛和僵硬，可同时累及周围关节和中轴关节，常呈非对称性分布。70%的关节炎就诊时有银屑病病史，80-90%伴有甲病变。实验室检查没有特征性的变化，类风湿因子（RF）、抗核抗体（ANA）和抗瓜氨酸肽抗体（ACPA）大多呈阴性。《荟萃分析：银屑病关节炎关节外表现的患病率》Rheumatology，2020年9月 (2)研究的目的是评价银屑病关节炎关节外症状的流行情况（肌腱炎、指炎、指甲疾病、葡萄膜炎和炎症性肠病），及其对纵向疾病结局的影响。研究纳入65项研究，共计163 299例银屑病关节炎患者。在进行报道的文献中，肌腱炎平均发病率为30%，指炎平均发病率为25%，甲疾病发病率为60%，葡萄膜炎为3.2%，炎症性肠病3.3%。其中，合并指炎的患者影像学进展的可能性增加。结论：银屑病关节炎患者中，常合并肌腱炎、指炎和甲病；而葡萄膜炎和炎症性肠病不常见。《真实世界：银屑病或银屑病关节炎患者严重感染的风险》Annals of Rheumatic Diseases，2020年2月 (3)研究的目的是使用IL-17、IL-12/23或肿瘤坏死因子（TNF）抑制剂，是否与银屑病或银屑病关节炎患者严重感染风险的增加有关。研究共包括11560个新的治疗事件，9264人年的随访。研究共发现190例严重感染（占治疗期的2%），IL-17和TNF抑制剂的感染发生率相似，而IL-12/23抑制剂则明显降低（风险比0.59）。在曾经使用过生物制剂的患者中，各组感染风险无差异。结论：相对于TNF和IL-17抑制剂，IL-12/23抑制剂可以降低银屑病或银屑病关节炎患者的严重感染的风险。《纵向队列研究：银屑病性关节炎的DAPSA、颈动脉斑块和心血管事件》Annals of Rheumatic Diseases，2020年11月 (4)研究的目的是评价反映银屑病关节炎炎症成分的银屑病关节炎的疾病活动评分（DAPSA）是否能够预测心血管事件，而不依赖于传统的心血管危险因素和亚临床颈动脉粥样硬化。研究纳入189例银屑病关节炎患者，平均年龄48.9岁。平均9.9年的随访后，较高的银屑病关节炎的疾病活动评分与心血管事件的风险增加显著相关（风险比 1.04， p=0.009），在多变量模型中调整所有心血管风险后，这种关联仍然有统计学意义。亚组分析中，调整其他心血管风险后，颈动脉斑块与发生CV事件的风险增加显著相关（风险比 3.42）。结论：较高的DAPSA和CP的存在可以独立预测银屑病关节炎患者的心血管事件事件，这种风险不依赖于传统的心血管疾病风险。小羽点评：银屑病性关节炎不仅累及皮肤、关节，还可能增加感染和心血管疾病的发生风险，在临床实践中，需要对银屑病关节炎的患者进行多个系统的功能进行跟踪和随访。银屑病关节炎的治疗银屑病关节炎中，外周关节炎常使用NSAID治疗；若效果不佳，常采用传统改变病情的抗风湿药物（DMARD），如甲氨蝶呤（MTX）、来氟米特（LEF）；若多个关节侵蚀及功能受限，建议使用生物性DMARD，如TNF抑制剂为一线治疗（依那西普、阿达木单抗、英夫利西单抗、塞妥珠单抗和戈利木单抗）。一种TNF抑制剂无效时，可换用另一种TNF抑制剂；两种TNF抑制剂无效时，可使用IL-17抑制剂（苏金单抗、依奇珠单抗）、IL-12/23抑制剂（优特克单抗）、T细胞共刺激调节因子（阿巴西普）、JAK抑制剂（托法替尼）。累及骶髂关节和脊柱关节、附着点炎时，通常不推荐使用传统DMARD。银屑病关节炎患者一般应避免使用糖皮质激素，因为可能增加红皮病或脓疱型银屑病的几率。《回顾性队列研究：传统合成抗风湿药治疗银屑病性关节炎中，单药保留甲氨蝶呤优于柳氮磺胺吡啶》Rheumatology，2020年8月 (5)比较传统合成抗风湿药物的疗效和使用时间的研究有限，此研究的目的是比较一线传统合成抗风湿药物单药治疗的银屑病关节炎的药物保留和药物保留的预测因子。文章回顾性的研究了首次使用传统抗风湿药物作为单一药物治疗银屑病关节炎的187例患者，主要终点是治疗失败、停止用药或添加另一个抗风湿药物的时间。患者中单药使用甲氨蝶呤共163人，单药使用柳氮磺胺吡啶共21人，平均药物保留事件为31.8个月。其中甲氨蝶呤平均使用34.5个月，柳氮磺胺吡啶平均使用12.0个月（P =0.016）。使用甲氨蝶呤的患者中，随着年龄增长药物保留率逐渐增加。治疗失败的主要原因是无效(52%)和副作用(28%)。结论：在临床实践中，甲氨蝶呤单药治疗银屑病关节炎优于柳氮磺胺吡啶。《GO-DACT研究：治疗银屑病关节炎患者的指炎方面，戈利木单抗联合甲氨蝶呤优于单用甲氨蝶呤》Annals of Rheumatic Diseases，2020年4月 (6)戈利木单抗是一种抗肿瘤坏死因子α单抗，研究的目的是评价戈利木单抗联合甲氨碘呤和单用甲氨蝶呤治疗银屑病性关节炎指炎的疗效。这个多中心、随机、双盲、安慰剂对照、平行设计的3b期试验中，银屑病关节炎伴有活动性指炎的患者被分配到戈利木单抗或安慰剂组，两者均与甲氨蝶呤联合使用。24周后，与甲氨蝶呤单药治疗相比，戈利木单抗联合甲氨蝶呤显著改善指炎的临床症状（指炎严重程度评分变化分别为5和2，p = 0.026）。联合治疗组的指炎严重程度评分改善50%或70%的患者和Leeds指炎指数改善20%、50%或70%的患者比例显著高于单用甲氨蝶呤的患者。结论：戈利木单抗联合甲氨蝶呤作为一线生物抗风湿治疗银屑病指炎优于甲氨蝶呤单药治疗。《荟萃分析：生物制剂对银屑病关节炎患者外周关节影像学进展的影响》Rheumatology，2020年11月 (7)研究的目的是确定生物制剂在预防银屑病关节炎患者、外周关节影像学进展中的有效性。研究包括11项临床试验，涉及5382名患者，9种药物和18种治疗方法。与安慰剂相比，接受生物制剂的患者更有可能实现影像学无进展（优势比2.40，其中TNF抑制剂的优势比 2.94，IL抑制剂的优势比 2.15，阿巴西普的优势比 1.54）。生物制剂显著降低了外周关节影像学进展的风险（影像学进展评分平均下降-2.16，其中TNF抑制剂下降 -2.82，IL抑制剂下降 -1.60，阿巴西普下降 -0.40。生物制剂联合甲氨蝶呤的方案，并不优于单一生物制剂治疗的效果；尤特克单抗和苏金单抗的疗效，不受先前抗TNK治疗的影响。结论：与安慰剂相比，生物制剂可能在骨侵蚀和关节间隙狭窄方面延缓银屑病关节炎患者的影像学进展。甲氨蝶呤似乎没有额外的获益；先前的抗肿瘤坏死因子治疗似乎不会影响IL抑制剂的治疗效果。上一次的节目介绍了IL-17抑制剂（苏金单抗、依奇珠单抗）最近刚刚被FDA批准用于治疗中轴型脊柱关节炎，今天来和大家聊一聊IL-17A单抗在银屑病关节炎中的应用，以及比较这两个药物和肿瘤坏死因子抑制剂阿达木单抗的头对头研究。《Future 5研究：苏金单抗治疗银屑病性关节炎的3期研究结果》Rheumatology，2020年6月 (8)研究目的是评估苏金单抗治疗银屑病性关节炎52周后患者的影像学进展。纳入的银屑病性关节炎参与者，既往没有治疗过、或者TNF-α抑制剂无效，被随机分入苏金单抗 300mg组、150mg组、150mg无负荷给药组或安慰剂组，前4周q1w负荷给药，4周后q4w给药。其中300mg组有91.8%的患者52周后，没有出现影像学进展；在150mg组和150mg无负荷给药组中，这里比例分别是85.2%和87.2%。苏金单抗 300mg组、150mg组和150mg无负荷给药组中，影像学vdH-mTSS评分的随机斜率为-0.18、0.11和-0.20。临床疗效持续稳定，52周内没有报告新的或意料之外的安全事件。结论：苏金单抗 300mg、150mg和150mg无负荷剂量组，治疗银屑病性关节炎显示出持续稳定的低进展率。《SPIRIT-P1研究：依奇珠单抗治疗活动性银屑病关节炎患者的III期临床试验3年结果》Rheumatology，2020年2月 (9)研究的目的是评估长达156周的依奇珠单抗（IL-17A单抗）治疗银屑病关节炎的安全性和有效性。银屑病关节炎患者被随机分配到安慰剂组、阿达木单抗或依奇珠单抗q2w或q4w组。在第24周时，阿达木单抗和安慰剂组的患者被重新随机分配到依奇珠单抗q2w或q4w组，并继续延长治疗至第156周，共243例患者完成了为期3年的研究。依奇珠单抗q2w组患者治疗紧急和严重不良事件的发生率分别为38.0%和5.2%，依奇珠单抗q4w组患者为38.1%和8.0%。156周时，两组患者ACR响应≥20%的比例占69.8%和62.5%；响应≥50%的比例为51.8%和56.1%，响应≥70%的比例为33.4%和43.8%。银屑病面积和严重程度指数（PASI）缓解75%的占（63.5%和69.1）；缓解90%的展51.2%和64.5；缓解100%的占43.6%和60.5%。直至156周，在q2w组中的61%和q4w组中的71%的患者，影像学进展得到抑制。结论：依奇珠单抗治疗156周后，其安全性与之前的报道保持一致，并且观察到银屑病关节炎患者症状和体征的持续改善，包括影像学进展率持续较低。《EXCEED研究：头对头比较苏金单抗与阿达木单抗治疗银屑病关节炎疗效的3b期试验》Lancet，2020年5月 (10)EXCEED研究评估了苏金单抗与阿达木单抗作为一线生物单药治疗活动性银屑病关节炎患者的安全性和有效性。这个平行、双盲、多中心、主动对照的3b阶段的研究，招募18岁以上的、活动性银屑病关节炎患者，主要终点是52周时ACR反应标准至少改善20%（ACR20）。研究过程中853例患者完成了52周的研究，研究结束后，苏金单抗组14%和阿达木单抗组24%的患者选择停止使用研究中的治疗方案。第52周时，67%的苏金单抗组患者和62%的阿达木单抗组患者达到治疗的主要终点，两组间无统计学差异。苏金单抗组2%和阿达木单抗组1%的患者出现严重感染，苏金单抗出现一例与研究药物无关的死亡，其他的安全性与之前报道一致。结论：苏金单抗与阿达木单抗的疗效没有统计学差异，但是苏金单抗的治疗保留率更高。《SPIRIT研究：头对头比较依奇珠单抗和阿达单抗治疗银屑病关节炎的疗效和安全性》Annals of Rheumatic Diseases，2020年7月 (11)SPIRIT研究头对头的比较了依奇珠单抗（IL-17A单抗）和阿达单抗治疗银屑病关节炎的有效性和安全性。 研究纳入566例银屑病关节炎的患者，将患者随机分为依奇珠单抗和阿达单抗治疗组，评价标准是24周和52周时，患者ACR反应标准改善50%（ACR50）和银屑病面积和严重度评分改善100%（PASI100）。52周时，依奇珠单抗治疗组中同时达到ACR50和PASI100的患者的比例显著高于阿达木单抗 (39% vs 26%， p

FDA 批准卡那单抗用于治疗成人Still病Lancet 苏金单抗与阿达木单抗治疗银屑病关节炎的头对头比较Arthri & Rheumatol重组腺苷脱氨酶可改善系统性硬化症模型的纤维化卡那单抗（canakinumab）上周一的心脏科专题中，我们聊到了冠心病的抗炎治疗最新进展，目前研究热点集中在IL-1β单克隆抗体卡那单抗和秋水仙碱。今天我们来聊一聊卡那单抗在免疫科中的应用。卡那单抗（canakinumab）最初于2009年被FDA批准用于治疗Cryopyrin相关周期性综合征（CAPS）、全身型幼年特发性关节炎以及三种少见的周期性发热综合征；2020年6月，卡那单抗被FDA批准用于治疗成人Still病。《卡那单抗用于治疗成人Still病以减少关节炎的表现：2期临床试验》Annals of Rheumatic Diseases，2020年8月 (1)这项多中心、双盲、随机、安慰剂对照试验，旨在评价其治疗成人Still病的有效性和安全性。研究纳入19名多关节受累的成人Still病患者，随机给予卡那单抗和安慰剂治疗。基线时，卡那单抗组和安慰剂组的平均疾病活动评分为5.4和5.3。在卡那单抗组中，61%的患者达到30%应答率，50%的患者达到50%应答率，28%的患者达到70%应答率；而对照组仅为20%、6.7%和0%（p=0.033，0.009和0.049)。卡那单抗组的两名患者经历了严重的不良事件。结论：卡那单抗治疗可改善多项成人Still病的疗效指标。银屑病性关节炎银屑病关节炎（psoriatic arthritis，PsA）是一种与银屑病有关的炎症性肌肉骨骼疾病。主要表现为受累关节疼痛和僵硬，可同时累及周围关节和中轴关节，常呈非对称性分布。70%的关节炎就诊时有银屑病病史，80-90%伴有甲病变。实验室检查没有特征性的变化，类风湿因子（RF）、抗核抗体（ANA）和抗瓜氨酸肽抗体（ACPA）大多呈阴性。《荟萃分析：银屑病关节炎关节外表现的患病率》Rheumatology，2020年9月 (2)研究的目的是评价银屑病关节炎关节外症状的流行情况（肌腱炎、指炎、指甲疾病、葡萄膜炎和炎症性肠病），及其对纵向疾病结局的影响。研究纳入65项研究，共计163 299例银屑病关节炎患者。在进行报道的文献中，肌腱炎平均发病率为30%，指炎平均发病率为25%，甲疾病发病率为60%，葡萄膜炎为3.2%，炎症性肠病3.3%。其中，合并指炎的患者影像学进展的可能性增加。结论：银屑病关节炎患者中，常合并肌腱炎、指炎和甲病；而葡萄膜炎和炎症性肠病不常见。《真实世界：银屑病或银屑病关节炎患者严重感染的风险》Annals of Rheumatic Diseases，2020年2月 (3)研究的目的是使用IL-17、IL-12/23或肿瘤坏死因子（TNF）抑制剂，是否与银屑病或银屑病关节炎患者严重感染风险的增加有关。研究共包括11560个新的治疗事件，9264人年的随访。研究共发现190例严重感染（占治疗期的2%），IL-17和TNF抑制剂的感染发生率相似，而IL-12/23抑制剂则明显降低（风险比0.59）。在曾经使用过生物制剂的患者中，各组感染风险无差异。结论：相对于TNF和IL-17抑制剂，IL-12/23抑制剂可以降低银屑病或银屑病关节炎患者的严重感染的风险。《纵向队列研究：银屑病性关节炎的DAPSA、颈动脉斑块和心血管事件》Annals of Rheumatic Diseases，2020年11月 (4)研究的目的是评价反映银屑病关节炎炎症成分的银屑病关节炎的疾病活动评分（DAPSA）是否能够预测心血管事件，而不依赖于传统的心血管危险因素和亚临床颈动脉粥样硬化。研究纳入189例银屑病关节炎患者，平均年龄48.9岁。平均9.9年的随访后，较高的银屑病关节炎的疾病活动评分与心血管事件的风险增加显著相关（风险比 1.04， p=0.009），在多变量模型中调整所有心血管风险后，这种关联仍然有统计学意义。亚组分析中，调整其他心血管风险后，颈动脉斑块与发生CV事件的风险增加显著相关（风险比 3.42）。结论：较高的DAPSA和CP的存在可以独立预测银屑病关节炎患者的心血管事件事件，这种风险不依赖于传统的心血管疾病风险。小羽点评：银屑病性关节炎不仅累及皮肤、关节，还可能增加感染和心血管疾病的发生风险，在临床实践中，需要对银屑病关节炎的患者进行多个系统的功能进行跟踪和随访。银屑病关节炎的治疗银屑病关节炎中，外周关节炎常使用NSAID治疗；若效果不佳，常采用传统改变病情的抗风湿药物（DMARD），如甲氨蝶呤（MTX）、来氟米特（LEF）；若多个关节侵蚀及功能受限，建议使用生物性DMARD，如TNF抑制剂为一线治疗（依那西普、阿达木单抗、英夫利西单抗、塞妥珠单抗和戈利木单抗）。一种TNF抑制剂无效时，可换用另一种TNF抑制剂；两种TNF抑制剂无效时，可使用IL-17抑制剂（苏金单抗、依奇珠单抗）、IL-12/23抑制剂（优特克单抗）、T细胞共刺激调节因子（阿巴西普）、JAK抑制剂（托法替尼）。累及骶髂关节和脊柱关节、附着点炎时，通常不推荐使用传统DMARD。银屑病关节炎患者一般应避免使用糖皮质激素，因为可能增加红皮病或脓疱型银屑病的几率。《回顾性队列研究：传统合成抗风湿药治疗银屑病性关节炎中，单药保留甲氨蝶呤优于柳氮磺胺吡啶》Rheumatology，2020年8月 (5)比较传统合成抗风湿药物的疗效和使用时间的研究有限，此研究的目的是比较一线传统合成抗风湿药物单药治疗的银屑病关节炎的药物保留和药物保留的预测因子。文章回顾性的研究了首次使用传统抗风湿药物作为单一药物治疗银屑病关节炎的187例患者，主要终点是治疗失败、停止用药或添加另一个抗风湿药物的时间。患者中单药使用甲氨蝶呤共163人，单药使用柳氮磺胺吡啶共21人，平均药物保留事件为31.8个月。其中甲氨蝶呤平均使用34.5个月，柳氮磺胺吡啶平均使用12.0个月（P =0.016）。使用甲氨蝶呤的患者中，随着年龄增长药物保留率逐渐增加。治疗失败的主要原因是无效(52%)和副作用(28%)。结论：在临床实践中，甲氨蝶呤单药治疗银屑病关节炎优于柳氮磺胺吡啶。《GO-DACT研究：治疗银屑病关节炎患者的指炎方面，戈利木单抗联合甲氨蝶呤优于单用甲氨蝶呤》Annals of Rheumatic Diseases，2020年4月 (6)戈利木单抗是一种抗肿瘤坏死因子α单抗，研究的目的是评价戈利木单抗联合甲氨碘呤和单用甲氨蝶呤治疗银屑病性关节炎指炎的疗效。这个多中心、随机、双盲、安慰剂对照、平行设计的3b期试验中，银屑病关节炎伴有活动性指炎的患者被分配到戈利木单抗或安慰剂组，两者均与甲氨蝶呤联合使用。24周后，与甲氨蝶呤单药治疗相比，戈利木单抗联合甲氨蝶呤显著改善指炎的临床症状（指炎严重程度评分变化分别为5和2，p = 0.026）。联合治疗组的指炎严重程度评分改善50%或70%的患者和Leeds指炎指数改善20%、50%或70%的患者比例显著高于单用甲氨蝶呤的患者。结论：戈利木单抗联合甲氨蝶呤作为一线生物抗风湿治疗银屑病指炎优于甲氨蝶呤单药治疗。《荟萃分析：生物制剂对银屑病关节炎患者外周关节影像学进展的影响》Rheumatology，2020年11月 (7)研究的目的是确定生物制剂在预防银屑病关节炎患者、外周关节影像学进展中的有效性。研究包括11项临床试验，涉及5382名患者，9种药物和18种治疗方法。与安慰剂相比，接受生物制剂的患者更有可能实现影像学无进展（优势比2.40，其中TNF抑制剂的优势比 2.94，IL抑制剂的优势比 2.15，阿巴西普的优势比 1.54）。生物制剂显著降低了外周关节影像学进展的风险（影像学进展评分平均下降-2.16，其中TNF抑制剂下降 -2.82，IL抑制剂下降 -1.60，阿巴西普下降 -0.40。生物制剂联合甲氨蝶呤的方案，并不优于单一生物制剂治疗的效果；尤特克单抗和苏金单抗的疗效，不受先前抗TNK治疗的影响。结论：与安慰剂相比，生物制剂可能在骨侵蚀和关节间隙狭窄方面延缓银屑病关节炎患者的影像学进展。甲氨蝶呤似乎没有额外的获益；先前的抗肿瘤坏死因子治疗似乎不会影响IL抑制剂的治疗效果。上一次的节目介绍了IL-17抑制剂（苏金单抗、依奇珠单抗）最近刚刚被FDA批准用于治疗中轴型脊柱关节炎，今天来和大家聊一聊IL-17A单抗在银屑病关节炎中的应用，以及比较这两个药物和肿瘤坏死因子抑制剂阿达木单抗的头对头研究。《Future 5研究：苏金单抗治疗银屑病性关节炎的3期研究结果》Rheumatology，2020年6月 (8)研究目的是评估苏金单抗治疗银屑病性关节炎52周后患者的影像学进展。纳入的银屑病性关节炎参与者，既往没有治疗过、或者TNF-α抑制剂无效，被随机分入苏金单抗 300mg组、150mg组、150mg无负荷给药组或安慰剂组，前4周q1w负荷给药，4周后q4w给药。其中300mg组有91.8%的患者52周后，没有出现影像学进展；在150mg组和150mg无负荷给药组中，这里比例分别是85.2%和87.2%。苏金单抗 300mg组、150mg组和150mg无负荷给药组中，影像学vdH-mTSS评分的随机斜率为-0.18、0.11和-0.20。临床疗效持续稳定，52周内没有报告新的或意料之外的安全事件。结论：苏金单抗 300mg、150mg和150mg无负荷剂量组，治疗银屑病性关节炎显示出持续稳定的低进展率。《SPIRIT-P1研究：依奇珠单抗治疗活动性银屑病关节炎患者的III期临床试验3年结果》Rheumatology，2020年2月 (9)研究的目的是评估长达156周的依奇珠单抗（IL-17A单抗）治疗银屑病关节炎的安全性和有效性。银屑病关节炎患者被随机分配到安慰剂组、阿达木单抗或依奇珠单抗q2w或q4w组。在第24周时，阿达木单抗和安慰剂组的患者被重新随机分配到依奇珠单抗q2w或q4w组，并继续延长治疗至第156周，共243例患者完成了为期3年的研究。依奇珠单抗q2w组患者治疗紧急和严重不良事件的发生率分别为38.0%和5.2%，依奇珠单抗q4w组患者为38.1%和8.0%。156周时，两组患者ACR响应≥20%的比例占69.8%和62.5%；响应≥50%的比例为51.8%和56.1%，响应≥70%的比例为33.4%和43.8%。银屑病面积和严重程度指数（PASI）缓解75%的占（63.5%和69.1）；缓解90%的展51.2%和64.5；缓解100%的占43.6%和60.5%。直至156周，在q2w组中的61%和q4w组中的71%的患者，影像学进展得到抑制。结论：依奇珠单抗治疗156周后，其安全性与之前的报道保持一致，并且观察到银屑病关节炎患者症状和体征的持续改善，包括影像学进展率持续较低。《EXCEED研究：头对头比较苏金单抗与阿达木单抗治疗银屑病关节炎疗效的3b期试验》Lancet，2020年5月 (10)EXCEED研究评估了苏金单抗与阿达木单抗作为一线生物单药治疗活动性银屑病关节炎患者的安全性和有效性。这个平行、双盲、多中心、主动对照的3b阶段的研究，招募18岁以上的、活动性银屑病关节炎患者，主要终点是52周时ACR反应标准至少改善20%（ACR20）。研究过程中853例患者完成了52周的研究，研究结束后，苏金单抗组14%和阿达木单抗组24%的患者选择停止使用研究中的治疗方案。第52周时，67%的苏金单抗组患者和62%的阿达木单抗组患者达到治疗的主要终点，两组间无统计学差异。苏金单抗组2%和阿达木单抗组1%的患者出现严重感染，苏金单抗出现一例与研究药物无关的死亡，其他的安全性与之前报道一致。结论：苏金单抗与阿达木单抗的疗效没有统计学差异，但是苏金单抗的治疗保留率更高。《SPIRIT研究：头对头比较依奇珠单抗和阿达单抗治疗银屑病关节炎的疗效和安全性》Annals of Rheumatic Diseases，2020年7月 (11)SPIRIT研究头对头的比较了依奇珠单抗（IL-17A单抗）和阿达单抗治疗银屑病关节炎的有效性和安全性。 研究纳入566例银屑病关节炎的患者，将患者随机分为依奇珠单抗和阿达单抗治疗组，评价标准是24周和52周时，患者ACR反应标准改善50%（ACR50）和银屑病面积和严重度评分改善100%（PASI100）。52周时，依奇珠单抗治疗组中同时达到ACR50和PASI100的患者的比例显著高于阿达木单抗 (39% vs 26%， p

Dr. Reda Bassali, professor of pediatrics and pediatric hospitalist at the Medical College of Georgia, joins Dr. Zac Hodges and Gavriella Mendel (M3) to discuss this very important topic in pediatric medicine. What exactly is bronchiolitis and why is this topic so important? How do you make the diagnosis and what other diagnoses should you consider? What treatments work, and more importantly, which treatments do not? What patients can go home and who needs to be admitted? All of this and more from the Department of Pediatrics and the Medical College of Georgia.  Check out our website for detailed show-notes: https://www.augusta.edu/mcg/pediatrics/residency/podcast.php Special thanks to Dr. Kathryn McLeod for providing peer review for this episode. Citation: Hodges, Z. (Host). Bassali, R. (Host).  Mendel, G. (Host). McLeod, K. (Contributor). (2020, Nov 15). Bronchiolitis. (S1:18) [Audio Podcast Episode]. MCG Pediatric Podcast. Medical College of Georgia Augusta. Questions, comments, or feedback? Please email us at mcgpediatricpodcast@augusta.edu  Links:  NoseFrida-- https://www.nosefrida.com  References/further reading: Silver AH, Nazif JM. Bronchiolitis. Pediatr Rev. 2019;40(11):568-576. doi:10.1542/pir.2018-0260   Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis [published correction appears in Pediatrics. 2015 Oct;136(4):782]. Pediatrics. 2014;134(5):e1474-e1502. doi:10.1542/peds.2014-2742  Florin TA, Plint AC, Zorc JJ. Viral bronchiolitis. Lancet. 2017;389(10065):211-224. doi:10.1016/S0140-6736(16)30951-5   Cunningham S, Rodriguez A, Adams T, et al. Oxygen saturation targets in infants with bronchiolitis (BIDS): a double-blind, randomised, equivalence trial. Lancet. 2015;386(9998):1041-1048. doi:10.1016/S0140-6736(15)00163-4 Franklin D, Babl FE, Schlapbach LJ, Oakley E, Craig S, Neutze J, Furyk J, Fraser JF, Jones M, Whitty JA, Dalziel SR, Schibler A. A Randomized Trial of High-Flow Oxygen Therapy in Infants with Bronchiolitis. N Engl J Med. 2018 Mar 22;378(12):1121-1131. doi: 10.1056/NEJMoa1714855. PMID: 29562151. Lin J, Zhang Y, Xiong L, Liu S, Gong C, Dai J. High-flow nasal cannula therapy for children with bronchiolitis: a systematic review and meta-analysis. Arch Dis Child. 2019 Jun;104(6):564-576. doi: 10.1136/archdischild-2018-315846. Epub 2019 Jan 17. PMID: 30655267.

FDA 连续批准2个CGRP受体拮抗剂治疗急性偏头痛NEJM 中国41家三甲医院参加的DIRECT-MT研究NEJM 连续发表2种脊髓侧索硬化症在研新疗法瑞美吉泮（rimegepant）降钙素基因相关肽（CGRP）受体位于疼痛信号通路、颅内动脉和肥大细胞中，其活化被认为在偏头痛的病理生理学中起着因果作用。例如，偏头痛发作时血清中CGRP水平升高。瑞美吉泮（rimegepant）是一种新型的口服、小分子血管舒张剂-CGRP受体拮抗剂。2020年2月，FDA批准瑞美吉泮用于治疗偏头痛急性发作。《随机对照研究：瑞美吉泮治疗急性偏头痛的3期临床研究》Lancet，2020年8月 (1)在这项双盲、随机、安慰剂对照、多中心的第三期试验中，纳入偏头痛病史≥1年的、偏头痛患者1466人，被随机分配接受瑞美吉泮口腔崩解片75mg 和安慰剂治疗。给药后2小时，瑞美吉泮口腔崩解片在止痛方面优于安慰剂（21%对11%，p

FDA 连续批准2个CGRP受体拮抗剂治疗急性偏头痛NEJM 中国41家三甲医院参加的DIRECT-MT研究NEJM 连续发表2种脊髓侧索硬化症在研新疗法瑞美吉泮（rimegepant）降钙素基因相关肽（CGRP）受体位于疼痛信号通路、颅内动脉和肥大细胞中，其活化被认为在偏头痛的病理生理学中起着因果作用。例如，偏头痛发作时血清中CGRP水平升高。瑞美吉泮（rimegepant）是一种新型的口服、小分子血管舒张剂-CGRP受体拮抗剂。2020年2月，FDA批准瑞美吉泮用于治疗偏头痛急性发作。《随机对照研究：瑞美吉泮治疗急性偏头痛的3期临床研究》Lancet，2020年8月 (1)在这项双盲、随机、安慰剂对照、多中心的第三期试验中，纳入偏头痛病史≥1年的、偏头痛患者1466人，被随机分配接受瑞美吉泮口腔崩解片75mg 和安慰剂治疗。给药后2小时，瑞美吉泮口腔崩解片在止痛方面优于安慰剂（21%对11%，p

Osteoarthritis of the hands;Whole joint disease;Benjamin concepts' about osteoarthritis;References:1.Alizai H, Walter W, Khodarahmi I, Burke CJ. Cartilage Imaging in Osteoarthritis. Semin Musculoskelet Radiol. 2019;23(5):569-78.2.Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745-59.3.Roemer FW, Crema MD, Trattnig S, Guermazi A. Advances in imaging of osteoarthritis and cartilage. Radiology. 2011;260(2):332-54.4.Sophia Fox AJ, Bedi A, Rodeo SA. The basic science of articular cartilage: structure, composition, and function. Sports Health. 2009;1(6):461-8.5.Pathria MN, Chung CB, Resnick DL. Acute and Stress-related Injuries of Bone and Cartilage: Pertinent Anatomy, Basic Biomechanics, and Imaging Perspective. Radiology. 2016;280(1):21-38.6.Huber M, Trattnig S, Lintner F. Anatomy, biochemistry, and physiology of articular cartilage. Invest Radiol. 2000;35(10):573-80.7.Martinez-Moreno D, Jimenez G, Galvez-Martin P, Rus G, Marchal JA. Cartilage biomechanics: A key factor for osteoarthritis regenerative medicine. Biochim Biophys Acta Mol Basis Dis. 2019;1865(6):1067-75.8.Amin S, LaValley MP, Guermazi A, Grigoryan M, Hunter DJ, Clancy M, et al. The relationship between cartilage loss on magnetic resonance imaging and radiographic progression in men and women with knee osteoarthritis. Arthritis Rheum. 2005;52(10):3152-9.9.Braun HJ, Gold GE. Diagnosis of osteoarthritis: imaging. Bone. 2012;51(2):278-88.10.Guermazi A, Burstein D, Conaghan P, Eckstein F, Hellio Le Graverand-Gastineau MP, Keen H, et al. Imaging in osteoarthritis. Rheum Dis Clin North Am. 2008;34(3):645-87.11.Argentieri EC, Burge AJ, Potter HG. Magnetic Resonance Imaging of Articular Cartilage within the Knee. J Knee Surg. 2018;31(2):155-65.12.Zhang Y, Niu J, Kelly-Hayes M, Chaisson CE, Aliabadi P, Felson DT. Prevalence of symptomatic hand osteoarthritis and its impact on functional status among the elderly: The Framingham Study. Am J Epidemiol. 2002;156(11):1021-7.13.N S. Hand Osteoarthritis — Clinical Presentation, Phenotypes and Management. 2015.14.Tan AL, Grainger AJ, Tanner SF, Shelley DM, Pease C, Emery P, et al. High-resolution magnetic resonance imaging for the assessment of hand osteoarthritis. Arthritis Rheum. 2005;52(8):2355-65.15.Mathiessen A, Slatkowsky-Christensen B, Kvien TK, Hammer HB, Haugen IK. Ultrasound-detected inflammation predicts radiographic progression in hand osteoarthritis after 5 years. Ann Rheum Dis. 2016;75(5):825-30.16.Okano T, Mamoto K, Di Carlo M, Salaffi F. Clinical utility and potential of ultrasound in osteoarthritis. Radiol Med. 2019;124(11):1101-11.17.Hammer HB, Iagnocco A, Mathiessen A, Filippucci E, Gandjbakhch F, Kortekaas MC, et al. Global ultrasound assessment of structural lesions in osteoarthritis: a reliability study by the OMERACT ultrasonography group on scoring cartilage and osteophytes in finger joints. Ann Rheum Dis. 2016;75(2):402-7.18.Benjamin M, McGonagle D. The anatomical basis for disease localisation in seronegative spondyloarthropathy at entheses and related sites. J Anat. 2001;199(Pt 5):503-26.19.McGonagle D, Tan AL, Carey J, Benjamin M. The anatomical basis for a novel classification of osteoarthritis and allied disorders. J Anat. 2010;216(3):279-91.20.McGonagle D, Hermann KG, Tan AL. Differentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy era. Rheumatology (Oxford). 2015;54(1):29-38.21.Grainger AJ, Farrant JM, O'Connor PJ, Tan AL, Tanner S, Emery P, et al. MR imaging of erosions in interphalangeal joint osteoarthritis: is all osteoarthritis erosive? Skeletal Radiol. 2007;36(8):737-45.

Nebojša je odsutan. Miloš pokušava da prevede svoje predavanje o Covid-19 i pacijentima sa rakom na srpski. Izvori: 1. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–3. 2. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science. 2020:eabb2762. 3. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–3. 4. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med. 2020. 5. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). Science. 2020:eabb3221. 6. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England). 2020 7. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. J Clin Invest. 2020. 8. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. Jama. 2020. 9. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. medRxiv. 2020:2020.04.23.20076042. 10. Collaborative TO, Williamson E, Walker AJ, Bhaskaran KJ, Bacon S, Bates C, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv. 2020:2020.05.06.20092999. 11. Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020. 12. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak. Cancer Discov. 2020. Linkovi: 1. The Covid-19 and cancer consortium (https://ccc19us.org) 2. ASCO Covid-19 resources (https://www.asco.org/asco-coronavirus-information) 3. ASH Covid-19 resources (https://www.hematology.org/covid-19)